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Abstract 
Tuberculosis is an increasing threat, owing to the spread of AIDS and to the development of 
resistance of the causative organism, Mycobacterium tuberculosis, to the currently available 
drugs. Dihydrofolate reductase (DHFR) is an important enzyme of the folate cycle; inhibition 
of DHFR inhibits growth and causes cell death. The crystal structure of M. tuberculosis 
DHFR revealed a glycerol tightly bound close to the binding site for the substrate dihydro-
folate; this glycerol-binding motif is absent from the human enzyme. A series of pyrimidine-
2,4-diamines was designed with a two-carbon tether between a glycerol-mimicking triol and 
the 6-position of the heterocycle; these compounds also carried aryl substituents at the 5-pos-
ition. These, their diastereoisomers, analogues lacking two hydroxy groups and analogues 
lacking the two-carbon spacing linker were synthesised by acylation of the anions derived 
from phenylacetonitriles with ethyl (4S,5R)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-
4-propanoate, ethyl (4S,5S)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-4-propanoate, 
tetrahydrooxepin-2-one and 2,3-O-isopropylidene-D-erythronolactone, respectively, to give 
the corresponding α-acylphenylacetonitriles. Formation of the methyl enol ethers, condensat-
ion with guanidine and deprotection gave the pyrimidine-2,4-diamines. Preliminary assay of 
the abilities of these compounds to inhibit the growth of TB5 Saccharomyces cerevisiae 
carrying the DHFR genes from M. tuberculosis, human and yeast indicated that 5-phenyl-6-
((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine selectively inhibited M. tuberculosis 
DHFR and had little effect on the human or yeast enzymes. 
                                                 
† Present address: Faculty of Pharmacy, Tanta University, Tanta, Egypt 
‡ Present address: School of Pharmacy, University of London, 29-39 Brunswick Square, London, UK 
1. Introduction 
Tuberculosis (TB) is responsible for the highest number of deaths of all infectious diseases.1 
Rates of TB continue to rise, leading to an estimated eight million new cases every year and 
an annual death toll of two million.2 Several factors have contributed to this increase, such as 
the HIV pandemic.3 Current therapy (DOTS) consists of an initial phase with four drugs, 
isoniazid, rifampin, pyrazinamide and ethambutol daily for two months, followed by a 
continuation phase of treatment with isoniazid and rifampin thrice weekly for a further four 
months, and has a cure rate of up to 95%, given patient compliance.4 Poor patient compliance 
with this prolonged regimen, together with other factors, has led to the emergence of 
multidrug-resistant tuberculosis (MDR-TB), against which DOTS is relatively ineffective.5,6 
In view of this, DOTS-Plus (DOTS plus second-line TB drugs) is now recommended for 
treating MDR-TB and TB in areas with high incidence of MDR-TB.4 However, DOTS-Plus is 
expensive, takes longer to administer and has significant side-effects.7 
Dihydrofolate reductase (DHFR) is an important enzyme in the folate cycle8,9 which supplies 
one-carbon units derived from the action of serine hydroxymethyltransferase10,11 on L-serine 
for the biosynthesis of deoxythymidine monophosphate (dTMP). Inhibition of the folate cycle 
leads to interruption of the supply of thymidine and thus to inhibition of DNA biosynthesis 
and inhibition of proliferation of cells. Inhibition of proliferation is a useful goal in the ther-
apy of cancer12 and of bacterial and protozoal infections.13 Highly potent inhibition of DHFR 
Figure 1. Structures of the DHFR substrate dihydrofolate 1 and the inhibitors methotrexate 2, pyrimethamine 
3, DDMP / metoprine 4a, etoprine 4b, methylbenzoprim 5 and trimethoprim 6. 
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has been achieved with analogues of the substrate, dihydrofolate 1 (Figure 1). Methotrexate 2 
is a highly potent inhibitor of mammalian DHFR and mammalian tumour DHFR (IC50 = 2.5 
nM vs. rat liver DHFR)14 and is one of the most widely used anticancer antimetabolite drugs. 
It has ca. seven-fold selectivity for inhibition of human DHFR vs. M. tuberculosis DHFR.15  
The biological activities of pyrimidine-2,4-diamines have shown that it is not necessary to 
have the full pteridinediamine structure. These “non-classical” inhibitors have advantages in 
that they are more lipophilic than 2 and can enter cells by passive diffusion, not requiring the 
folate carrier. Pyrimethamine 3 was developed over 50 years ago as a DHFR-inhibiting anti-
malarial drug;16 it has selectivity for inhibition of Plasmodium falciparum DHFR activity of 
ca. forty-fold vs. human DHFR.17 It is several orders of magnitude less potent than 2 against 
human DHFR.17-19 Sulphadoxine / pyrimethamine plus isoniazid has some utility as prophyl-
axis against tuberculosis in HIV-positive pateints20 but isoniazid itself has been implicated in 
inhibition of M. tuberculosis DHFR after metabolism.21 DDMP / metoprine 4a is a close anal-
ogue of 3 which shows a similar profile of inhibition of DHFRs, showing some activity as an 
antitumour agent in clinical trial.22 However, this compound is also a highly potent inhibitor 
of histamine N-methyltransferase,23,24 leading to neurological complications with its use. The 
6-ethyl analogue etoprine 4b shows similar antileukaemic activity;25 its inhibition of testicular 
DHFR causes infertility in male rats.26 Methylbenzoprim 5 was designed as a non-classical 
DHFR inhibitor which lacks the full pteridine ring structure of methotrexate 2 but remains 
extremely potent against mammalian DHFRs (IC50 vs. rat liver DHFR 3.2 pM) with some 
antitumour activity.14 Interestingly, this compound is markedly less active against Pneumo-
cystis carinii, Toxoplasma gondii and Escherichia coli DHFRs;14,18 these activities have been 
rationalised in a crystallographic and modelling study.18 Trimethoprim 6, in which the 5-aryl 
substituent is linked through a methylene bridge for increased flexibility, is often cited as an 
inhibitor of M. tuberculosis DHFR and other bacterial DHFRs, yet it is reported to lack 
potency (IC50 16.5 μM) and to be only five-fold selective for inhibition of M. tuberculosis 
DHFR vs. the human enzyme.15 There is thus a great need for rationally designed selective 
inhibitors of M. tuberculosis DHFR for treatment of this widespread and often fatal disease. 
2. Structure-based design 
Several groups have pointed to structural differences between M. tuberculosis DHFR and 
human DHFR as possible opportunities for the design of selective inhibitors15,27-29 but few 
studies have exploited these differences successfully in rational drug design for TB.30 Da 
Cunha et al.30  have suggested that addition of hydrophobic groups to 5-deazapteridines 
should increase selectivity, based on six examples. Suling et al.31 have achieved >100-fold 
selectivity for inhibition of the M. avium DHFR vs. human DHFR using similar 5-methyl-5-
deazapteridine-2,4-diamines but have not published results for M. tuberculosis DHFR. Thus 
the way is open for rational structure-based design of selective inhibitors of M. tuberculosis 
DHFR exploiting a major difference between human and M. tuberculosis enzyme structures.  
Li et al. reported crystal structures of M. tuberculosis DHFR. One structure contains metho-
trexate 2 bound at the dihydrofolate-binding site and NADP+ at the NADP+-binding site but 
also contains a glycerol tightly bound in an adjacent pocket where it forms H-bonds with 
Asp27, Gln28 and Leu24 (Figure 2A).28 This glycerol is also present in the structure of M. tub-
erculosis DHFR with the 1,3,5-triazine-2,4-diamine inhibitor Br-WR99210 bound but is 
absent from the crystal of M. tuberculosis DHFR containing 6, probably owing to the fact that 
the trimethoxyphenyl unit causes the trimethoprim to bind in a different manner, causing the 
Gln28 side-chain to be disordered.28  A more detailed examination of the environment of the 
glycerol reveals additional H-bonds (Figure 2B), as indicated by O—O and O—N distances 
and appropriate orientations. O(1)—H makes a H-bond with the side-chain amide carbonyl 
oxygen of Asp27; O(1) is also involved as an acceptor in a H-bond with the indole N—H of 
Figure 2. Images of structures of DHFR from M. tuberculosis, with methotrexate 2 bound at the dihydrofolate-
binding site. A: View of the structure of M. tuberculosis DHFR with 2 bound, showing the glycerol molecule 
bound close to the active site (crystal structure reported by Li et al.28) (glycerol and 2 are shown as rods and 
balls; DHFR is shown as a surface with blue cationic, red anionic and grey hydrophobic neutral). B: Proposed 
H-bonds from the bound glycerol to the residues surrounding the glycerol pocket (atoms within 3.9 Ǻ of the 
glycerol are shown as rods; other atoms and bonds are shown as wires). 
Trp22. O(3) is also held in a two-H-bond clamp; O(3)—H makes a H-bond with the carbonyl 
oxygen of Leu24 and is also an acceptor in a H-bond with the N—H of the same amino-acid. 
O(2) accepts a single H-bond from the side-chain amide N—H of Gln28. The glycerol carbon 
chain is in hydrophobic contact with Leu20.28 In contrast, in the structures of human DHFR 
complexes containing dihydrofolate or 2, this site is well packed with hydrophobic side-
chains.32,33 Since this glycerol is clearly tightly and specifically bound in a fixed conformation 
close to N(8) of 2, we designed series of molecules in which contain a 1,2,3-triol joined to a 
head group which would mimic the binding of  2 deep in the dihydrofolate-binding pocket. 
Since 3 is a weak inhibitor of M. avium DHFR activity34 and many other pyrimidine-2,4-di-
amines inhibit various DHFRs, we chose pyrimidine-2,4-diamine as the template to which to 
attach the linker from the triol. Compounds 7 (Scheme 1) were designed directly from model-
ling the orientation of the glycerol and overlay of the pyrimidine-2,4-diamine unit with the di-
aminopteridine of 2. This overlay suggested that a two-carbon linker (-CH2CH2-) would be 
optimum to join the triol to the pyrimidine 6-position; it also showed the need for R configur-
ation at the C(3) secondary alcohol of the 3,4,5-trihydroxypentyl side-chain (mimicking 
glycerol O(1)) and S configuration at the C(4) secondary alcohol (mimicking glycerol O(2)), 
as in 7. The diastereomeric series 8 is S at C(3); this series tests the validity of the drug 
design, since the linker length is the same as in 7 but the orientation of the triol relative to the 
Scheme 1. Structures of designed pyrimidine-2,4-diamines 7-12 and retrosynthetic analysis. 
R = 3R,4S-3,4,5-trihydroxypentyl, 3S,4S-3,4,5-trihydroxypentyl, 5-hydroxypentyl, 1S,2R-1,2,3-
trihydroxypropyl, Ph(CH2)2, Me
a: R3 = R4 = H; b: R3 = H, R4 = Cl; c: R3 = H, R4 = Br; d: R3 = R4 = Cl.
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pyrimidine-diamine should not be apposite for binding. In 9, the secondary alcohols are 
missing, leaving only the primary alcohol of the 6-(5-hydroxypentyl) group to mimic O(3) of 
the glycerol and H-bond to Leu24 in the glycerol-binding pocket, losing the ability to H-bond 
to Trp22, Asp27 and Gln28, but retaining possible hydrophobic interactions with Leu20. The 
length of the linker between the triol and the pyrimidine-2,4-diamine is tested in the 6-(1,2,3-
trihydroxypropyl) compounds 10; these compounds retain the triol motif with the same 
configuration at the secondary alcohols as in 7 but joined directly to pyrimidine C(6). 
In each of the sets of 6-((poly)hydroxyalkyl)pyrimidine-2,4-diamines 7-10, a phenyl is locat-
ed at position-5 of the pyrimidine, to occupy a (largely) hydrophobic pocket which the hinge 
region (-CH2NMe-) of 2 occupies in Figure 2A. This phenyl is unsubstituted in 7a-10a, 
whereas this ring is halogenated in other designed compounds. It carries a 4’-chlorine in 7b-
10b (reflecting the 4’-chlorine in 3) and a 4’-bromine in 7c-10c. 3’,4’-Dichlorophenyl was 
incorporated into 7d, 9d and 10d to mimic the dichlorophenyl in 4a,b; the corresponding an-
alogue in the 8 series was planned but was synthetically inaccessible. Compounds 11 and 12 
(Scheme 1) were designed as gross tests of the structure-based design of inhibitors, while ret-
aining the essential pyrimidine-2,4-diamine. In 11, the designed triol is replaced by a hydro-
phobic aromatic benzene ring which should interact unfavourably with the H-bonding envir-
onment of the glycerol-binding pocket. In 12, there is no group which may enter this pocket.  
3. Chemical synthesis 
3.1. Synthetic strategy 
The planned synthetic approaches to the series of target pyrimidine-2,4-diamines 7-12 are 
shown in retrosynthetic format in Scheme 1. In each case, condensation of an appropriately 
substituted corresponding enol ether 13 with guanidine would furnish the pyrimidinediamine. 
The enol ethers would be readily prepared by methylation of the α-acylphenylacetonitriles 14, 
which, in turn would be available by acylation of anions derived from (Ar-substituted)phenyl-
acetonitriles 15 with the appropriate esters 16, with or without protection of the side-cahin 
alcohols. Several questions needed to be addressed during the development of the synthetic 
routes: how should the condensation with guanidine be optimised? how should the acylation 
be optimised? do the primary and secondary alcohols in the side-chains need to be protected 
during the acylation or condensation steps? if so, what should the protecting groups be? We 
elected to use the general synthetic approach, condensation of guanidine with enol ethers 
derived from α-acylphenylacetonitriles, used by Russell and Hitchings16 in their syntheses of 
pyrimethamine 3, etoprine 4 and related antimalarial compounds carrying simple small-alkyl 
substituents at the 6-position of the pyrimidine-2,4-diamine core. Tarnchompoo et al.19 have 
extended this synthetic approach to analogues carrying larger alkyl and ω-arylalkyl groups at 
this position, in their search for pyrimidine-2,4-diamines which inhibit DHFR activity in 
Plasmodium falciparum which is resistant to 3. The acylation steps and the protection of the 
OH groups were optimised individually for each series of target compounds.  
3.2. Synthesis of 5-aryl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamines 7 
Scheme 2 shows our approach to the 5-aryl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-
2,4-diamines 7, using protection for the primary alcohol. We rationalised that the ester 21 
would provide the required masked triol at the 6-position and could be synthesised by a two-
carbon chain extension from a protected L-erythrose 18. Acetonide protection was introduced 
between the cis 3-OH and 4-OH of L-arabinose 17 by acid-catalysed reaction with 2,2-
dimethoxypropane. Oxidative cleavage of the C(1)—C(2) bond with periodate then gave L-
erythrose-2,3-acetonide 18. The required two-carbon chain-extension was achieved by base-
free Wittig reaction of the latent aldehyde of 18 with pre-formed ethyl triphenyl-
phosphoranylidineacetate to afford the stereoisomeric α,β-unsaturated esters 19E and 19Z in 
69% overall yield (ratio of geometrical isomers 3:11, 19E and 19Z, respectively). These geo-
metrical isomers were readily separated chromatographically and were identified on the basis 
of the 1H NMR coupling constants in the –HC=CH- system. Separation of the isomers was 
unnecessary in the synthetic plan, as catalytic hydrogenation of the mixture of 19E and 19Z 
gave the saturated ester 20 quantitatively. 1H NMR spectroscopy confirmed the presence of 
only one diastereoisomer of 20. A variety of protecting groups was investigated for the 
primary alcohol; we proposed that this alcohol should not be exposed during the reaction of 
the ester with the carbanion derived from the phenylacetonitriles, to avoid possible quenching 
of the carbanion and to avoid lactonisation of the hydroxy-ester 20. The primary alcohol of 20 
was benzylated by generation of the alkoxide with lithium bis(trimethylsilyl)amide and react-
ion with benzyl bromide to give the fully protected ester 21. The classical conditions for using 
esters to acylate phenylacetonitrile carbanions,16 sodium ethoxide in ethanol, failed to effect 
the required reaction. However, the carbanions were generated from the (halo)phenylaceto-
nitriles under aprotic conditions with lithium bis(trimethylsilyl)amide in diethyl ether at low 
temperature; these reacted with 21 to afford the α-acylphenylacetonitriles 22a-d in 16-26% 
yields. The 1H NMR spectra indicated the presence of varying amounts of the enol tautomers 
23a-d. Methylation with diazomethane gave the enol ethers 24a-d as inseparable mixtures of 
geometrical isomers. Condensation of these mixtures with guanidine in boiling 2-methoxy-
ethanol then led to the pyrimidine-2,4-diamines 25a-d in satisfactory yields; similar reactions 
in the conventional solvent for these condensations, ethanol, gave lower yields. 
Removal of the acetonide protection from 25a-d with aq. trifluoroacetic acid revealed the sec-
ondary alcohols in 26a-d in excellent yields but subsequent removal of the benzyl protection 
from the primary alcohol was more challenging. Catalytic hydrogenolysis (H2, Pd/C, various 
solvents) failed to remove the benzyl group from 26a, even in the presence of catalytic per-
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Scheme 2. Synthetic routes to 5-aryl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamines 7, using Bn 
protection for the primary OH and omitting protection for the primary OH. Reagents: i, Me2C(OMe)2, TsOH, 
DMF; ii, NaIO4, H2O, hexane; iii, EtO2CCH=PPh3, CH2Cl2; iv, H2, Pd/C, EtOH; v, LiN(SiMe3)2, BnBr, THF, 
DMF; vi, LiN(SiMe3)2, ArCH2CN, Et2O; vii, CH2N2, Et2O; viii, guanidine.HCl, NaOMe, MeO(CH2)2OH; ix, 
aq. CF3CO2H; x, Na, liquid NH3, xi, FeCl3, CH2Cl2. 
chloric acid. However, addition of a catalytic amount of chloroform35 to the hydrogenolysis 
reaction mixture in methanol facilitated the deprotection to give triol 7a. This method could 
not be extended to debenzylation of the halogen-bearing analogues 26b-d, as hydrogenolysis 
of the carbon—halogen bonds occurred; 26b and 26c gave 7a only, whereas 26d gave an in-
separable mixture of 7a, 7b and the meta-monochloro analogue. Attempted debenzylation 
with hydrogen bromide in acetic acid, another common method, gave regioisomeric mixtures 
of bromo- and acetoxy-pentylpyrimidine-2,4-diamines. The most effective method for prepar-
ation of the Ar-unsubstituted analogue 7a was reductive cleavage of the O—benzyl protecting 
group with sodium in liquid ammonia. This method could not be extended to preparation of 
the halogenated congeners 7b-d, as reduction of the carbon—halogen bonds led to exclusive 
formation of the phenyl analogue 7a from 26b-d. The most generally applicable debenzylat-
ion for this series was the use of the Lewis acid anhydrous iron(III) chloride in dichloro-
methane, as developed by Park et al.36 By this method, 26b-d were converted in high yields 
into the required triols 7b-d. Moreover, the Lewis acidity of this reagent could be exploited 
also in removal of the acetonides, in that both acetonide and benzyl ether protecting groups 
could be removed from 25a-d in one pot to furnish 7a-d directly, albeit in lower overall yields 
than in the two-step processes. TLC analysis suggested that, in this one-pot process, the aceto-
nide was cleaved within 5 min and the debenzylation was essentially complete within 80 min. 
In view of these challenges, the assembly of the pyrimidine ring was attempted with a free 
primary alcohol in the side chain. As shown in Scheme 2, the phenylacetonitriles were deprot-
onated with lithium bis(trimethylsilyl)amide and the anions were quenched with the ester 20. 
Use of two equivalents of base was necessary to achieve condensation to obtain the α-acyl-
phenylacetonitriles 27 in a maximum yield of 10%, indicating that protection of the primary 
alcohol is beneficial for this acylation to proceed efficiently. Methylation of the tautomeric 
enols 28 with diazomethane and condensation of the enol ethers 29 with guanidine gave the 
pyrimidine-2,4-diamines 30. Again, the yields were significantly lower with the exposed 
primary alcohol (30a: 42%, 30b: 12%, 30c: 20%, 30d: 9%). Deprotection was straightforward 
to furnish the target triols 7. 
3.3. Synthesis of 5-aryl-6-((3S,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamines 8 
The approach to the diastereomeric 5-aryl-6-((3S,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-
diamines 8 was broadly similar to that for 7, using the benzyl protection method. In this series 
(Scheme 3), the key intermediate was the trans dioxolane 38, a diastereomer of the cis 
dioxolane ester 21 above. The approach to 38 started with protection of the secondary alco-
hols of diethyl R,R-tartrate 31 as the acetonide 32; these secondary alcohols will become the 
secondary alcohols of the targets 8 with the appropriate configurations. Reduction with lith-
ium aluminium hydride furnished the C2-symmetric diol 33. Mono-protection of this diol was 
essential for developing the chain-extension of only one arm. The optimum conditions were 
found to be deprotonation with one equivalent of sodium hydride in DMF, followed by alkyl-
ation with benzyl chloride, giving the required monoether 35, with a trace of diether 34. Pyr-
idinium chlorochromate oxidation converted the exposed alcohol to the aldehyde 36, which 
was immediately condensed with ethyl triphenylphosphoranylidineacetate in a Wittig reaction 
to give the chain-extended α,β-unsaturated esters 37E and 37Z. In contrast to the analogous 
uncatalysed formation of 19E and 19Z (which carry free primary alcohols) at ambient temper-
Scheme 3. Synthesis of 5-aryl-6-((3S,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamines 8. Reagents: i, 
Me2C(OMe)2, TsOH, 4 Å molecular sieve, CH2Cl2; ii, LiAlH4, THF; iii, NaH, BnCl, DMF; iv, PCC, NaOAc, 
4 Å molecular sieve, CH2Cl2; v, EtO2CCH=PPh3, PhCO2H, PhMe, Δ; vi, H2, Pd/C, EtOH; vii, LiN(SiMe3)2, 
ArCH2CN, Et2O; viii, CH2N2, Et2O; ix, guanidine.HCl, NaOMe, MeO(CH2)2OH; x, aq. CF3CO2H; xi, H2, 
Pd/C, EtOH; xii, FeCl3, CH2Cl2. 
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ature, this reaction required prolonged heat-
ing at 110°C and catalysis with benzoic 
acid. In this case, the mixture of the separ-
able geometrical isomers 37E and 37Z was 
approximately equimolar. Careful control of 
the hydrogenation conditions was required 
to reduce the alkene of the 37E / 37Z mix-
ture to form key intermediate 38 without 
causing loss of the benzyl protecting group 
through hydrogenolysis. The fully protected 
ester 38 was then used, as for the diastereo-
mer 21, to alkylate the carbanions derived 
from the (halo)phenylacetonitriles to afford 
the α-acylphenylacetonitriles 39a-c; 3,4-di-
chlorophenylacetonitrile failed to react. Methylation of the enols 40 and condensation of the 
enol ethers 41 with guanidine led to the pyrimidine-2,4-diamines 42, in much higher yields 
(42a: 67%, 42b: 48%, 42c: 53%) than in the R,S series. The side-chain alcohols were deprot-
ected in two steps. Acid-hydrolysis of the acetonide rapidly gave the diols 43. As in the dia-
stereomeric series, hydrogenolysis removed the benzyl group from 43a to afford 8a in high 
yield; debenzylation with iron(III) chloride converted 43b and 43c to the triols 8b and 8c, res-
pectively, avoiding the dehalogenations associated with other debenzylation procedures. 
3.4. Synthesis of 5-aryl-6-(5-hydroxypentyl)pyrimidine-2,4-diamines 9 
Although a similar approach of protection of the primary alcohol could have been used in the 
syntheses of 6-(5-hydroxypentyl)pyrimidine-2,4-diamines 9, a strategy was devised to use a 
lactone to provide the necessary acylating ester, simultaneously masking the primary alcohol 
(Scheme 4). The carbanions of the (halo)phenylacetonitriles were generated in the usual way 
with lithium bis(trimethylsilyl)amide; the yields of the reactions with lactone 44 to give the α-
(6-hydroxyhexanoyl)phenylacetonitriles 45 were low but provided sufficient material for 
further methylation of the enols 46 and condensation of 47 with guanidine to give the required 
6-(5-hydroxypentyl)pyrimidines 9 in moderate yields. No deprotection steps were required in 
this series as the primary alcohols had been revealed during the reaction of the lactone with 
the phenylacetonitrile anions. 
Scheme 4. Synthesis of 5-aryl-6-(5-hydroxypentyl)-
pyrimidine-2,4-diamines 9. Reagents: i, LiN(SiMe3)2, 
ArCH2CN, Et2O; ii, CH2N2, Et2O; iii, guanidine.HCl, 
NaOMe, MeO(CH2)2OH. 
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3.5. Synthesis of 5-aryl-6-((1S,2R)-1,2,3-
trihydroxypropyl)pyrimidine-2,4-di-
amines 10 
The lactone strategy was also used for the 
chain-shortened triols 10 (Scheme 5). 2,3-
O-Isopropylidene-D-erythronolactone 48 
reacted with the phenylacetonitriles anions 
to afford 49 in 21-38% yields. In the usual 
way, methylation of the enols 50, condens-
ations of the enol ethers 51 with guanidine 
and aqueous acid deprotection of 52 gave 
the pyrimidine-2,4-diamines 10 carrying 
the 6-((1S,2R)-1,2,3-trihydroxypropyl) 
side-chains. 
The dioxolanylpyrimidine intermediates 52 
carry two bulky groups in close proximity 
in the 5- and 6-positions of the pyrimidine. 
MM2 energy minimisation suggests that 
this twists the 5-(4-halo)phenyl group in 
52a-c out of the pyrimidine plane by ca. 60° (Figure 3). The restricted rotation about the 
pyrimidine—Ph bond is evident in the NMR spectra of these compounds. The benzene ring is 
held close to the dioxolane, which bears two chiral centres. Thus the Ph 2-H and 6-H become 
diastereotopic, as do the Ph 3-H and 5-H. For example, in the 1H NMR spectrum of 52a, the 
Ph 2-H signal is separated from the Ph 6-H signal by 0.21 ppm, whereas the 3-H and 5-H 
signals are coincident. In the spectrum of the 4-chloro compound 52b, the Ph 2-H and 6-H 
signals are separated by 0.22 ppm and the 3-H and 5-H signals are separated by 0.04 ppm. In 
the spectrum of the 4-bromo compound 52c, the separations are 0.05 ppm and 0.02 ppm, 
respectively. In 52a-c, the substituents, if present, are in the 4-position of the benzene ring 
and are therefore coaxial with the pyrimidine—benzene bond. However, 52d carries a chlor-
ine atom in position-3 of the benzene ring, which is off the axis of this bond. Therefore, two 
different conformers 52dA and 52dB can exist, as shown in Figure 3 in stick and space-filling 
representations. Conformers 52dA and 52dB are diastereoisomers of very similar energy, 
Scheme 5. Synthesis of 5-aryl-6-((1S,2R)-1,2,3-tri-
hydroxypropyl)pyrimidine-2,4-diamines 10. Reagents: i, 
LiN(SiMe3)2, ArCH2CN, Et2O; ii, CH2N2, Et2O; iii, 
guanidine.HCl, NaOMe, MeO(CH2)2OH; iv, aq. 
CF3CO2H. 
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according to MM2 calculations. The 1H NMR spectrum of 52d shows the presence of both 
conformers in 1:1 ratio; the sharpness of the signals indicates that, as could be predicted from 
the severe steric crowding, interconversion is slow. The 1H signals for 2-H for the diastereo-
meric conformers are separated by 0.10 ppm, the signals for 5-H by 0.02 ppm and the signals 
for 6-H by 0.10 ppm. Other 1H NMR signals are co-incident for the two conformers, as are all 
the peaks in the 13C NMR spectrum. The latter was assigned by analogy with the spectra for 3 
and related compounds examined in detail earlier.37 This effect was not observed for the triols 
10a-d and only one set of signals could be seen for each compound, with 2-H and 6-H being 
magnetically equivalent. This probably reflects the greater flexibility in the triol side-chain. 
The effects were also not observed for the homologues 7 and 8, also owing to increased flex-
ibility and the remoteness of the chiral dioxolane from the benzene ring in these structures. 
52dA 52dB
52a
52b
52c
Figure 3.  MM2-minimised structures of pyrimidine-2,4-diamines 52a-d, showing the steric interactions 
between the 5-(halo)phenyl group and the 6-(2,2-dimethyl-5-hydroxymethyl-1,3-dioxolan-4-yl) substituent. As 
a result of this steric crowding, the (halo)phenyl group is twisted to ca. 60° from the plane of the pyrimidine. 
Compound 52d exists as two diastereomeric conformers, which are evident in the 1H and 13C NMR spectra. 
3.5. Synthesis of pyrimidine-2,4-di-
amines 11, 12 and 3, lacking OH in 
the 6-substituent 
Three pyrimidine-2,4-diamines 11, 12 
and 3, lacking alcohols in the 6-substit-
uent, were required as controls in the 
biological evaluation. The synthetic 
approaches followed the general sequ-
ence (Scheme 6). Acylation of phenyl-
acetonitrile anion with ethyl 2-phenyl-
propanoate 53, methylation of 55 and 
condensation of 56 with guanidine gave 
6-(2-phenylethyl)pyrimidine-2,4-di-
amine 11. The minimal analogue 12 was 
prepared similarly, through acylation of 
phenylacetonitrile anion with ethyl acet-
ate 57, methylation of 59 and condensat-
ion of 60 with guanidine. Finally, 3 was produced in a new route starting with generation of 
the anion from 4-chloroacetonitrile with LiN(SiMe3)2 and reaction with ethyl propanoate 61 
to give 62. Enol 63 was methylated, giving 64; condensation with guanidine in hot 2-meth-
oxyethanol provided 3 in good yield. 
4. Biological evaluation 
4.1. Inhibition of DHFR activities 
Direct screening of candidate drugs with M. tuberculosis is slow and requires biosafety Level 
3 facilities and procedures.38 The slow growth of M. tuberculosis has been frustrating, with 
most public health laboratories still employing cultivation techniques that require 3-6 weeks 
to achieve growth. This mainly reflects the slow generation time inherent in the organism. M. 
smegmatis and M. avium have often been used as surrogates for assessment of activity of can-
didate drugs, as they grow rapidly and are less pathogenic to humans.39-41 However, drug 
screening in wild-type M. smegmatis has not always been an accurate predictor of activity42 or 
of mechanism of action in M. tuberculosis.43 
Scheme 6. Synthesis of 5-phenyl-6-(2-phenylethyl)-
pyrimidine-2,4-diamine 11, 6-methyl-5-phenylpyrimidine-
2,4-diamine 12  and pyrimethamine 3. Reagents: i, 
LiN(SiMe3)2, ArCH2CN, Et2O; ii, CH2N2, Et2O; iii, 
guanidine.HCl, NaOMe, MeO(CH2)2OH. 
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A new approach to screening compounds for sel-
ective inhibition of DHFR from M. tuberculosis 
has been developed by Gerum et al.38 In this, the 
TH5 strain of the yeast Saccharomyces cerevis-
iae, which lacks endogenous expression of 
DHFR, was engineered to contain a vector 
p414CYC1 carrying a single copy of the dfrA 
gene from M. tuberculosis. This gene codes for 
the protein with DHFR activity in M. tuber-
culosis. The native TH5 strain of S. cerevisiae requires supplementation with dTMP, uracil, 
adenine and a full complement of amino acids to grow, whereas the engineered strain 
containing the dfrA gene can grow normally. Thus inhibition of the expressed M. tuberculosis 
DHFR activity would be manifest as inhibition of growth of the yeast. Two engineered TH5-
derived strains of S. cerevisiae were also engineered to carry yeast or human DHFR genes. In-
hibition of the growth of these yeasts by test compounds would indicate that these eukaryotic 
DHFRs are inhibited and would point to lack of selectivity for the prokaryotic M. tuberculosis 
enzyme. These three engineered yeasts were kindly supplied by Dr. Carol Hopkins Sibley 
(Department of Genome Sciences, University of Washington, Seattle, Washington, USA). 
Thus, in the present work, the test compounds were evaluated for their ability to inhibit 
selectively the growth of yeast carrying M. tuberculosis DHFR, while having less inhibition 
of yeast bearing either the yeast or the human enzyme. This assay, performed on a spoke 
assay plate, is semi-quantitative; comparison of the diameters of the zones of inhibition of the 
three yeasts by a particular test compound gives an indication of the selectivity of inhibition 
of the M. tuberculosis DHFR by that compound. Compounds can also be ranked approx-
imately for potency of inhibition, although no quantitative IC50 data can be derived. 
Table 1 shows the mean diameters of the zones of inhibition of growth of the three yeasts by 
the pyrimidine-2,4-diamines 7-10 carrying one or more alcohols in the side-chain, by the 
pyrimidine-2,4-diamines 11 and 12 with simple lipophilic side-chains and by the known 
DHFR-inhibiting pyrimidine-2,4-diamines 3 and 6. Data for the negative control, DMSO 
without drug, are also given. Trimethoprim 6 has been reported to have a broad spectrum of 
activity against gram-positive bacteria, including methicillin-sensitive (MSSA) and methic-
illin-resistant (MRSA) S. aureus, and gram negative bacteria, including E. coli, but less activ-
ity or no activity against Mycobacterium spp., Ps. aeruginosa and Chlamydia pneumoniae.44 
Figure 4. Typical plate (DMSO only control) 
showing orthogonal streaks of yeast after 3 d of 
incubation. 
At the enzymic level, 6 is only a weak inhibitor of M. avium DHFR and of eukaryotic DHFR 
but is potent in inhibiting DHFR activity in susceptible bacteria.41 In line with these reports, 6 
was found to be inactive against all three DHFRs in this yeast assay. Pyrimethamine 3 was 
very poorly active, even against the human enzyme, despite being reported to have Ki = 58 
nM against human DHFR.17 This observation suggests that, despite being only semi-quantit-
ative, the assay is a stringent test of inhibitory activity. The pyrimidine-2,4-diamine 11, which 
lacks hydroxy groups and carries only lipophilic substituents was also inactive against all the 
DHFRs. Interestingly, the minimal lipophilic pyrimidine-2,4-diamine 12, which bears only a 
methyl group at position-6, showed some inhibitory activity, although it was unselective. 
Pyrimidine-2,4-diamines 7a-d, which carry the (3R,4S)-3,4,5-trihydroxypentyl side-chain at 
the 6-position were designed to mimic directly the pteridine of the dihydrofolate and the glyc-
erol, with the configuration of each chiral centre being as predicted by the structure-based 
design; the –CH2CH2- linker is also of the length indicated by the modelling studies to be 
apposite. Within this set, the 5-phenyl compound 7a showed notable selectivity for inhibition 
of the growth of the yeast containing the M. tuberculosis DHFR, with only very modest inhib-
ition of the growth of the yeasts containing the H. sapiens enzyme or the S. cerevisiae 
enzyme. The 4’-chlorophenyl analogue 7b also showed some selectivity for inhibition of the 
M. tuberculosis enzyme, whereas the 4’-bromophenyl and 3’,4’-dichlorophenyl compounds 
7c and 7d had modest and equivalent activity against each DHFR. 
The diastereomeric series 8a-c showed modest activity but little evidence of selectivity. Rem-
oval of the secondary alcohols from the 6-position side-chain, in 9, led to compounds with in-
creased potency but completely lacking selectivity. In contrast, shortening the side-chain by 
removal of the –CH2CH2- linker but retaining the configuration of the secondary alcohols 
effectively abolished inhibitory activity in 9a-c but the 3’,4’-dichlorophenyl compound 9d 
showed modest but non-selective inhibition of all the DHFRs. 
Several trends are noticeable in the structure-activity relationships for these pyrimidine-2,4-
diamines. Firstly, comparison of the results for 7a,b with those for the diastereoisomers 8a,b 
indicates that the configuration of the hydroxy groups is critical for selective inhibition of M. 
tuberculosis DHFR, as predicted by the model. Secondly, the secondary alcohols appear to be 
necessary to use the binding contacts of one primary and the secondary alcohol of the glycer-
ol, in that the 6-(5-hydroxypentyl) compounds 9 are not selective for the M. tuberculosis enz-
yme. Thirdly, the length of the linker joining the dihydrofolate mimic (the pyrimidine-2,4-di-
amine) to the glycerol mimic is critical; shortening the distance in 10 abolishes activity. 
4.2. Modelling of the selective inhibitor 7a in the dihydrofolate- and glycerol-binding 
sites of M. tuberculosis DHFR 
The structures of selected pyrimidines from the series were modelled into the dihydrofolate-
binding site and the glycerol pocket, to attempt to rationalise the structure-activity observat-
ions and thus to validate the design process. The compounds were bound into the dihydrofol-
ate and glycerol binding pockets using the H-bonds from the pyrimidine-2,4-diamine ring to 
establish an orientation similar to the observed binding conformation of methotrexate 2.28  
The triol section was then docked using the H-bonds established from the bound glycerol in 
the X-ray structure (as distance restraints). Molecular dynamics calculations were then perfor-
med on the bound ligand using the H-bonds (X-ray observed) as distance restraints between 
the bound ligand and the pocket. The ligand was ramped to 300 K over a period of 10 ps and 
then held at 300 K for 20 ps. Observing the conformations over the final 20 ps gave two dist-
inct binding conformers. Throughout the above procedure, the binding pocket was restrained 
and only the ligand was allowed to change orientation. Average structures were taken (7-13 
ps and 15-20 ps) which were then minimised within a restrained binding pocket. The two 
structures obtained were then freely minimised (ligand and binding pocket to a radius of 15 
Å) to give the structures and conformations shown in Figure 5.  
Figure 5 shows the occupation of these sites by the two conformers of 7a, the most selective 
inhibitor of M. tuberculosis DHFR. As expected, the triol makes H-bonds with Asp27, Gln28, 
Leu24 and Trp22, following the pattern shown by the glycerol in the crystal structure.28 With 
the glycerol-mimicking triol held by the hydrogen-bonding network, the pyrimidine-2,4-di-
amine is perfectly located for its own hydrogen-bonding interactions deep in the dihydro-
folate-binding site. These constraints place the 5-phenyl substituent of 7a in a pocket of 
limited size. Indeed, this pocket cannot accomodate halogens in the 4’-position of the phenyl, 
as this position is tight against the surface of the enzyme; thus the observations that the 4’-
bromo- and 3’,4’-dichloro- analogues (7c and 7d, respectively) not selective inhibitors are rat-
ionalised in the model. The 4’-chloro- analogue 7b, however, does show slight selective in-
hibition of M. tuberculosis DHFR and it may be possible to accommodate the chlorine, albeit 
with a significant penalty in displacing the other binding contacts from their ideal positions. 
The active lead compound 7a can adopt two different conformations. As with all 5-(substitut-
ed)phenyl-6-substituted-pyrimidine-2,4-diamines, the 5-phenyl ring of 7a has to be twisted 
out of the plane of the aromatic heterocycle to accommodate the adverse steric interactions 
between the phenyl ortho-hydrogens and the adjacent 4-NH2 and 6-substituent. This rotation 
about the Ph—pyrimidine bond can be either clockwise or anticlockwise to achieve the same 
relief of steric strain. In conformer 7aA, the phenyl is rotated anticlockwise from coplanarity, 
whereas clockwise rotation produces 7aB; these conformers are almost identical in energy in 
free space. However, 7aA fits well into the pocket in the M. tuberculosis DHFR (Figure 5A), 
whereas the forward edge of the 5-phenyl of 7aB is located tightly pressed against the top of 
the enzyme pocket (Figure 5B). Thus the calculated energy of the complex of M. tuberculosis 
DHFR with conformer 7aA is of consistently higher energy than than of the complex of M. 
tuberculosis DHFR with conformer 7aB; indicating that 7a binds in conformer 7aA. 
5. Conclusions 
In this paper, we have reported our exploitation of a major difference in the local structure in 
the region of the dihydrofolate-binding sites of human and M. tuberculosis DHFR to design a 
compound 7a which shows notable selectivity for inhibition of the latter. In the crystal 
structure of a M. tuberculosis DHFR ternary complex with methotrexate 2 and glycerol, the 
glycerol is held tightly in its binding pocket by a network of five H-bonds. This glycerol-
binding pocket is close to the site of the methotrexate. This glycerol-binding pocket is absent 
from the structure of human DHFR. In the structures of 7, the two-carbon link suggested by 
the crystal structure joins a triol (mimicking the glycerol) to the 6-position of a pyrimidine-
Figure 5. Images of structures of DHFR from M. tuberculosis, with 7a bound at the dihydrofolate-binding site 
(structure derived from modelling study, see text). A: View of the structure of M. tuberculosis DHFR with 7a 
bound in conformation 7aA; B: View of the structure of M. tuberculosis DHFR with 7a bound in conformation 
7aB. 
2,4-diamine core which binds into the dihydrofolate-binding site. The configurations of the 
secondary alcohols match the orientation of the glycerol relative to the methotrexate in the 
crystal structure. Three series of analogues were also designed to test the hypotheses of the 
design of 7. Compounds 8 tested the assignment of the configuration of the point of attach-
ment of the triol to the linker and hence to the pyrimidine-2,4-diamine. Mono-hydroxy 
compounds 9 tested the need to take up the H-bonds from all three alcohols of the glycerol in 
binding selectively to the mycobacterial DHFR. Compounds 10 tested the length of the linker 
between the triol moiety and the pyrimidine-2,4-diamine. 
The target compounds were synthesised by acylation of the anions derived from phenylaceto-
nitriles with appropriately functionalised and protected esters and lactones, followed by 
methylation, condensation with guanidine and deprotection, if appropriate. The acylation step 
was optimised as generation of the phenylacetonitrile anion with lithium bis(trimethylsilyl)-
amide at -78°C, followed by addition of the ester or lactone. Yields under these optimised 
conditions ranged from 6% to 41%, with the lower yields being obtained with substrates con-
taining unprotected alcohols. The condensations with guanidine were generally uneventful 
and high yielding. Removal of benzyl groups presented a particular challenge, as many red-
uctive methods also effected dehalogenation in some analogues. 
Evaluation of the test 6-substituted pyrimidine-2,4-diamines for their inhibition of the growth 
of yeasts containing active DHFR from human, M. tuberculosis and yeast indicated that one 
compound, 7a, was selective for inhibition of M. tuberculosis DHFR and did not inhibit 
human DHFR or yeast DHFR significantly in the assay. Other compounds were inactive or 
less active. Modelling the structure of 7a into the dihydrofolate- and glycerol-binding pockets 
of M. tuberculosis DHFR rationalised the inhibition data, validating the original design of 
selective inhibitors and explaining the negative effect of halogenation of the 5-phenyl ring on 
biological activity. These modelling studies also indicated which of two low-energy con-
formations was required for binding and that there is a requirement for anticlockwise twist of 
the 5-phenyl ring relative to the pyrimidine. 5-Phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyr-
imidine-2,4-diamine 7a is shown here to be an interesting lead compound for further evalu-
ation and further refinement of design for optimisation of potency and selectivity of inhibition 
of M. tuberculosis DHFR and, hence, new approaches to treatment of this widespread disease. 
6. Experimental Section 
6.1. General 
NMR spectra were recorded on JEOL/Varian GX270 and EX400 spectrometers of samples in 
CDCl3, unless otherwise stated. Mass spectra were obtained using a VG7070E spectrometer. 
IR spectra were measured as thin films or as KBr discs on a Perkin-Elmer RXI FT-IR spectro-
meter. Optical rotations were measured in a 10 cm cell on an Optical Activity Ltd. polar-
imeter; c is expressed in g per 100 mL. The stationary phase for chromatography was silica 
gel. All reactions were carried out under N2 at ambient temperature, unless otherwise stated. 
Solvents were evaporated under reduced pressure. Melting points were determined by using a 
Reichert-Jung Thermo Galen instrument and are uncorrected. 
6.2. 1-(4-Chlorophenyl)-1-cyano-2-methoxybut-1-ene (64) and 5-(4-chlorophenyl)-6-
ethylpyrimidine-2,4-diamine (pyrimethamine) (3) 
Compound 62/63 was treated with CH2N2, as for the synthesis of 24a, to give 64 (88%) as a 
pale yellow oil: IR νmax 2204, 1606 cm-1; NMR 1.32 (3 H, t, J = 7.6 Hz, CMe), 2.80 (2 H, q, J 
= 7.6 Hz, CH2), 3.88 (3 H, s, OMe), 7.31 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 7.61 (2 H, d, J = 8.6 
Hz, Ph 2,6-H2). Compound 64 was treated with guanidine, as for the synthesis of 25a, to give 
3 (50%) as a white solid: mp 233-235ºC (lit.16 mp 233-234ºC); NMR δH 0.97 (3 H, t, J = 7.4 
Hz, Me), 2.09 (2 H, q, J = 7.4 Hz, CH2), 5.64 (2 H, br, NH2), 5.92 (2 H, br, NH2), 7.22 (2 H, 
d, J = 8.2 Hz, Ph 3,5-H2), 7.49 (2 H, d, J = 8.2 Hz, Ph 2,6-H2); MS m/z  251.0884 (M + H) 
(C12H1437ClN4 requires 251.0877), 249.0909 (M + H) (C12H1435ClN4 requires 311.0910). 
6.3. 5-Phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (7a). Method A 
Compound 26a (150 mg, 0.4 mmol) was treated with Na (84 mg, 3.6 mmol) in liquid NH3 (10 
mL) and THF (5 mL) at -33°C for 20 min. Saturated aq. NH4Cl (2 mL) was added and the 
mixture was allowed to warm to 20°C. CHCl3 (14 mL) and MeOH (7 mL) were added and the 
mixture was filtered. Evaporation and chromatography (CHCl3 / MeOH 7:3) gave 7a (90 mg, 
78%) as a white solid: mp 90-91°C; NMR (D2O) δH 1.29-1.36 (1H, m, 2-H), 1.49-1.55 (1H, 
m, 2-H), 2.07 (1H, ddd, J = 13.0, 10.2, 6.2 Hz, 1-H), 2.21 (1H, ddd, J = 13.0, 10.5, 5.3 Hz, 1-
H), 3.17-3.21 (1H, m, 3-H), 3.22-3.25 (2H, m, 5-H2), 3.37 (1H, dt, J = 8.5, 6.1 Hz, 4-H), 7.03 
(1H, d, J = 7.5 Hz, Ph 2-H), 7.04 (1H, d, J = 7.5 Hz, Ph 6-H), 7.23 (1H, t, J = 7.5 Hz, Ph 4-
H), 7.29 (2H, t, J = 7.5 Hz, Ph 3,5-H2); NMR (D2O) δC 30.24 (CH2), 31.10 (CH2), 62.25 (5-
C), 71.35 (CH), 74.11 (CH), 109.19 (Pyr 5-C), 128.08 (Ph CH), 129.19 (2 × Ph CH), 130.54 
(2 × Ph CH), 133.88 (Ph 1-C), 161.15 (Pyr 2-C), 162.92 (Pyr 4-C), 165.94 (Pyr 6-C); MS m/z 
305.1616 (M + H) (C15H21N4O3 requires 305.1613), 327 (M + Na), 243 (M - C2H5O2), 213 
(M – C3H7O3). 
6.4. 5-Phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (7a). Method B 
Compound 30a was treated with aq. CF3CO2H, as for the synthesis of 25a (reaction time 6 h), 
to give 7a (85%) as a white solid, with data as above. 
6.5. 5-(4-Chlorophenyl)-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (7b). 
Method A 
Compound 26b (60 mg, 0.14 mmol) was stirred with anhydrous FeCl3 (68 mg, 0.42 mmol) in 
dry CH2Cl2 (5 mL) under N2 for 80 min. Water (2 mL) was added. Evaporation and chromato-
graphy (CHCl3 / MeOH 7:3) gave 7b (30 mg, 63%) as a white solid: [α]20D = -1.0° (c 1.1, 
MeOH); mp 250-251°C; NMR (D2O) δH 1.44 (1 H, m, 2’-H), 1.65 (1 H, m, 2’-H), 2.22 (1 H, 
ddd, J = 13.6, 10.4, 6.0 Hz, 1’-H), 2.36 (1 H, ddd, J = 13.6, 10.0, 5.2 Hz, 1’-H), 3.31 (1 H, m, 
3’-H), 3.35-3.38 (2 H, m, 5’-H2), 3.48-3.53 (1 H, m, 4’-H), 7.18 (2 H, d, J = 8.6 Hz, Ar 2,6-
H2), 7.44 (2 H, d, J = 8.5 Hz, Ar 3,5-H2); NMR (CD3OD) δC 30.05, 31.36, 62.70, 71.97, 
74.14, 107.03, 129.18, 132.23, 133.13, 133.71, 161.73, 162.08, 163.06; MS m/z 341.1185 (M 
+ H) (C15H2037ClN4O3 requires 341.1194), 339.1225 (M + H) (C15H2035ClN4O3 requires 
339.1223), 308/306 (M - CH3OH), 249/247 (M – C3H7O3). 
6.6. 5-(4-Chlorophenyl)-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (7b). 
Method B 
Compound 30b was treated with aq. CF3CO2H, as for the synthesis of 7a, to give 7b (91%) as 
a white solid, with data as above. 
6.7. 5-(4-Bromophenyl)-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (7c). 
Method A 
Compound 26c was treated with FeCl3, as for the synthesis of 7b, to give 7c (85%) as a white 
solid: [α]20D = -4.2° (c 0.24, MeOH); mp 198-200°C; NMR (D2O) δH 1.47 (1 H, m, 2’-H), 
1.82 (1 H, m, 2’-H), 2.19 (1 H, m, 1’-H), 2.33 (1 H, m, 1’-H), 3.29 (1 H, m, 3’-H), 3.32-3.36 
(2 H, m, 5’-H2), 3.48 (1 H, m, 4’-H), 7.08 (2 H, d, J = 8.0 Hz, Ar 2,6-H2), 7.55 (2 H, d, J = 8.0 
Hz, Ar 3,5-H2); MS m/z 385.0683 (M + H) (C15H2081BrN4O3 requires 385.0698), 383.0714 (M 
+ H) (C15H2079BrN4O3 requires 383.0718). 
6.8. 5-(4-Bromophenyl)-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (7c). 
Method B 
Compound 30c was treated with aq. CF3CO2H, as for the synthesis of 7a, to give 7c (87%) as 
a pale yellow solid, with data as above. 
6.9. 5-(3,4-Dichlorophenyl)-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine 
(7d). Method A 
Compound 26d was treated with FeCl3, as for the synthesis of 7b, to give 7d (77%) as a white 
solid: [α]20D = -1.4° (c 2.2, MeOH); mp 180-181°C; NMR ((CD3)2SO) 1.43 (1 H, m, 2’-H), 
1.63 (1 H, m, 2’-H), 2.08 (1 H, ddd, J = 13.6, 10.4, 5.5 Hz, 1’-H), 2.34 (1 H, ddd, J = 13.6, 
10.4, 5.5 Hz, 1’-H), 3.17 (1 H, m, 3’-H), 3.28-3.31 (2 H, m, 5’-H2), 3.48 (1 H, m, 4’-H), 5.79 
(2 H, br, NH2), 5.97 (2 H, br, NH2), 7.16 (1 H, dd, J = 8.2, 1.8 Hz, Ar 6-H), 7.42 (1 H, d, J = 
1.8 Hz, Ar 2-H), 7.66 (1 H, d, J = 8.2 Hz, Ar 5-H); NMR ((CD3)2SO) δC 31.26, 32.09, 63.94, 
71.95, 75.19, 105.22, 131.38, 131.81, 133.16, 133.74, 133.97, 137.51, 162.42, 166.19; MS 
m/z 377.0794 (M + H) (C15H1937Cl2N4O3 requires 377.0775), 375.0814 (M + H) (C15H1937Cl 
35ClN4O3 requires 375.0804), 373.0836 (M + H) (C15H1935Cl2N4O3 requires 373.0834), 
345/343/341 (M - CH3O). 
6.10. 5-(3,4-Dichlorophenyl)-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine 
(7d). Method B 
Compound 30d was treated with aq. CF3CO2H, as for the synthesis of 7a, to give 7d (77%) as 
a white solid, with data as above. 
6.11. 5-Phenyl-6-((3S,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (8a) 
Compound 43a (200 mg, 0.5 mmol) was stirred in MeOH (20 mL) with Pd/C (5%, 154 mg) 
and CHCl3 (100 μL) under H2 for 2 h. Filtration (Celite®), evaporation and chromatography 
(CHCl3 / MeOH 7:3) gave 8a (150 mg, 93%) as a white solid: mp >350 °C; [α]20D = +10.9° (c 
0.5, H2O); NMR (D2O) δH 1.50-1.64 (2 H, m, 2’-H2), 2.28 (1 H, ddd, J = 13.9, 10.1, 6.3 Hz, 
1’-H), 2.40 (1 H, ddd, J = 13.9, 10.1, 6.3 Hz, 1’-H), 3.31-3.45 (4 H, m, 3’,4’,5’-H4), 7.25 (2 
H, d, J = 7.0 Hz, Ph 2,6-H2), 7.42 (1 H, t, J = 7.0 Hz, Ph 4-H), 7.47 (2 H, t, J = 7.0 Hz, Ph 3,5-
H2); NMR (D2O) δC 29.75, 31.57, 62.63, 73.61, 73.64, 109.24, 128.37, 129.37, 130.56, 
133.41, 160.29, 161.05, 161.81; MS m/z 305.1618 (M + H) (C15H21N4O3 requires 305.1613). 
6.12. 5-(4-Chlorophenyl)-6-((3S,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (8b) 
Compound 43b was treated with FeCl3, as for the synthesis of 7b, to give 8b (77%) as a white 
solid: mp >350 °C; [α]20D = +6.0° (c 0.67, H2O); NMR (CD3OD) δH 1.73-1.77 (2 H, m, 2’-
H2), 2.41 (1 H, dt, J = 14.4, 6.7 Hz, 1’-H), 2.54 (1 H, dt, J = 14.4, 6.7 Hz, 1’-H), 3.44-3.61 (4 
H, m, 3’,4’,5’-H4), 7.31 (2 H, d, J = 8.4 Hz, Ar 2,6-H2), 7.53 (2 H, d, J = 8.4 Hz, Ar 3,5-H2); 
NMR (CD3OD) δC 27.08, 31.39, 62.91, 70.52, 73.58, 108.29, 129.60, 132.04, 137.45, 137.50, 
156.86, 157.38, 157.80; MS m/z 341.1180 (M + H) (C15H2037ClN4O3 requires 341.1194), 
339.1237 (M + H) (C15H2035ClN4O3 requires 339.1223). 
6.13. 5-(4-Bromophenyl)-6-((3S,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine (8c) 
Compound 43c was treated with FeCl3, as for the synthesis of 7b, to give 8c (77%) as a white 
solid: mp >350 °C; [α]20D = +12.5° (c 0.24, MeOH); IR νmax 3649, 3468, 3418, 1618 cm-1; 
NMR (D2O) δH 1.60-1.72 (2 H, m, 2’-H2), 2.30-2.54 (2 H, m, 1’-H2), 3.42-3.56 (4 H, m, 
3’,4’,5’-H4), 7.25 (2 H, d, J = 8.7 Hz, Ar 2,6-H2), 7.72 (2 H, d, J = 8.7 Hz, Ar 3,5-H2); MS 
m/z 385.0707 (M + H) (C15H2081BrN4O3 requires 385.0698), 383.0717 (M + H) 
(C15H2079BrN4O3 requires 383.0718). 
6.14. 1-Cyano-7-hydroxy-2-methoxy-1-phenylhept-1-ene (47a) and 6-(5-hydroxypentyl)-
5-phenylpyrimidine-2,4-diamine (9a) 
Compound 45a/46a was treated with CH2N2, as for the synthesis of 24a (followed by chrom-
atography (EtOAc / hexane 2:1)), to give 47a (78%) as a pale yellow oil: IR νmax 3439, 2204 
cm-1; MS m/z 246.1492 (M + H) (C15H20NO2 requires 246.1494). Compound 47a was treated 
with guanidine, as for the synthesis of 25a (chromatographic eluant CH2Cl2 / MeOH (4:1)), to 
give 9a (36%) as a white solid: mp 214-216ºC; IR νmax 3420, 3331, 3177, 1619 cm-1; NMR δH 
1.27 (2 H, qn, J = 7.2 Hz, 3’-H2), 1.45 (2 H, qn, J = 7.2 Hz, 4’-H2), 1.55 (2 H, qn, J = 7.2 Hz, 
2’-H2), 2.28 (2 H, t, J = 7.2 Hz, 1’-H2), 3.56 (2 H, t, J = 6.4 Hz, 5’-H2), 4.59 (2 H, br, NH2), 
4.98 (2 H, br, NH2), 7.21 (2 H, d, J = 7.2 Hz, Ph 2,6-H2), 7.37 (1 H, t, J = 7.2 Hz, Ph 4-H), 
7.44 (2 H, t, J = 7.2 Hz, Ph 3,5-H2); NMR (CD3OD) δC 25.38, 28.49, 31.81, 33.79, 61.33, 
108.29, 127.67, 128.95, 130.51, 134.76, 161.32, 162.98, 165.09; MS m/z 273.1704 (M + H) 
(C15H20N4O requires 273.1715), 213 (M – C3H7O), 200 (M – C4H8O). 
6.15. 1-(4-Chlorophenyl)-1-cyano-7-hydroxy-2-methoxyhept-1-ene (47b) and 5-(4-
chlorophenyl)-6-(5-hydroxypentyl)pyrimidine-2,4-diamine (9b) 
Compound 45b/46b was treated with CH2N2, as for the synthesis of 24a (followed by chrom-
atography (EtOAc / hexane 3:1)), to give 47b (62%) as a pale yellow oil: NMR δH 1.52-1.80 
(6 H, m, 4,5,6-H6), 2.77 (2 H, t, J = 7.8 Hz, 3-H2), 3.68 (2 H, t, J = 6.2 Hz, 7-H2), 3.85 (3 H, s, 
Me), 7.29 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.54 (2 H, d, J = 8.6 Hz, Ar 3,5-H2); MS m/z 
282.1077 (M + H) (C15H1937ClNO2 requires 280.1074), 280.1102 (M + H) (C15H1935ClNO2 
requires 280.1104), 264/262 (M – OH). Compound 47b was treated with guanidine, as for the 
synthesis of 9a, to give 9b (59%) as a white solid: mp 165-166ºC; IR νmax 3407, 3329, 3174, 
1631 cm-1; NMR ((CD3)2SO) δH 1.11 (2 H, qn, J = 7.4 Hz, 3’-H2), 1.26 (2 H, qn, J = 7.4 Hz, 
4’-H2), 1.42 (2 H, qn, J = 7.4 Hz, 2’-H2), 2.07 (2 H, t, J = 7.4 Hz, 1’-H2), 3.29 (2 H, t, J = 7.4 
Hz, 5’-H2), 4.29 (1 H, br, OH), 5.64 (2 H, br, NH2), 5.94 (2 H, br, NH2) 7.18 (2 H, d, J = 8.2 
Hz, Ar 2,6-H2), 7.47 (2 H, d, J = 8.2 Hz, Ar 3,5-H2); NMR ((CD3)2SO) δC 25.88, 28.58, 
32.69, 34.63, 61.00, 106.16, 129.34, 132.25, 134.76, 133.10, 135.47, 162.44, 162.47, 165.87; 
MS m/z 309.1310 (M + H) (C15H2037ClN4O2 requires 309.1296), 307.1335 (M + H) 
(C15H2035ClN4O2 requires 307.1325), 236/234 (M - C4H8O). 
6.16. 1-(4-Bromophenyl)-1-cyano-7-hydroxy-2-methoxyhept-1-ene (47c) and 5-(4-bromo-
phenyl)-6-(5-hydroxypentyl)pyrimidine-2,4-diamine (9c) 
Compound 45c/46c was treated with CH2N2, as for the synthesis of 47b, to give 47c (32%) as 
a pale yellow oil: NMR δH 1.53-1.75 (6 H, m, 4,5,6-H6), 2.76 (2 H, t, J = 7.0 Hz, 3-H2), 3.69 
(2 H, t, J = 7.0 Hz, 7-H2), 3.85 (3 H, s, Me), 7.44 (2 H, d, J = 8.8 Hz, Ar 2,6-H2), 7.48 (2 H, d, 
J = 8.8 Hz, Ar 3,5-H2); MS m/z 326.0583 (M + H) (C15H1981BrNO2 requires 326.0578), 
324.0596 (M + H) (C15H1979BrNO2 requires 324.0599). Compound 47c was treated with 
guanidine, as for the synthesis of 9a, to give 9c (43%) as a white solid: mp 177-178ºC; IR 
νmax 3550, 3468, 3414, 1617 cm-1; NMR ((CD3)2SO) δH 1.11 (2 H, qn, J = 7.4 Hz, 3’-H2), 1.25 
(2 H, qn, J = 7.4 Hz, 4’-H2), 1.42 (2 H, qn, J = 7.4 Hz, 2’-H2), 2.07 (2 H, t, J = 7.4 Hz, 1’-H2), 
3.27 (2 H, t, J = 6.4 Hz, 5’-H2), 4.30 (1 H, br, OH), 5.74 (2 H, br, NH2), 6.00 (2 H, br, NH2), 
7.11 (2 H, d, J = 8.4 Hz, Ar 2,6-H2), 7.57 (2 H, d, J = 8.4 Hz, Ar 3,5-H2); NMR (CF3CO2H 
salt) ((CD3)2SO) δC 25.33, 27.72, 30.33, 32.21, 60.68, 108.00, 115.78 (q, J = 289.1 Hz), 
122.75, 130.74, 132.74, 133.24, 153.43, 155.31, 158 (q, J = 37.6 Hz), 164.30; MS m/z 
353.0807 (M + H) (C15H2081BrN4O requires 353.0800), 351.0816 (M + H) (C15H2079BrN4O 
requires 351.0820). 
6.17. 1-Cyano-1-(3,4-dichlorophenyl)-7-hydroxy-2-methoxyhept-1-ene (47d) and 5-(3,4-
dichlorophenyl)-6-(5-hydroxypentyl)pyrimidine-2,4-diamine (9d) 
Compound 45c/46c was treated with CH2N2, as for the synthesis of 47b, to give 47d (68%) as 
a pale yellow oil: NMR δH 1.41-1.50 (4 H, m, 5,6-H4), 1.62 (2 H, qn, J = 7.6 Hz, 4-H2), 2.75 
(2 H, t, J = 7.6 Hz, 3-H2), 3.41 (2 H, t, J = 6.0 Hz, 7-H2), 3.95 (3 H, s, Me), 7.50 (1 H, dd, J = 
8.6, 2.0 Hz, Ar 6-H), 7.63 (1 H, d, J = 8.6 Hz, Ar 5-H), 7.75 (1 H, d, J = 2.0 Hz, Ar 2-H); MS 
m/z 318.0686 (M + H) (C15H1837Cl2NO2 requires 318.0655), 316.0689 (M + H) 
(C15H1837Cl35ClNO2 requires 316.0685), 314.0715 (M + H) (C15H1835Cl2NO2 requires 
314.0714), 291/289/287 (M – CN). Compound 47d was treated with guanidine, as for the syn-
thesis of 9a, to give 9d (43%) as a white solid: mp 94-95ºC; IR νmax 3499, 3419, 3333, 1622 
cm-1; NMR ((CD3)2SO) δH 1.12 (2 H, qn, J = 7.4 Hz, 3’-H2), 1.25 (2 H, qn, J = 7.4 Hz, 4’-H2), 
1.42 (2 H, qn, J = 7.4 Hz, 2’-H2), 2.07 (2 H, t, J = 7.4 Hz, 1’-H2), 3.27 (2 H, q, J = 5.6 Hz, 5’-
H2), 4.28 (1 H, t, J = 5.6 Hz, OH), 5.72 (2 H, br, NH2), 5.90 (2 H, br, NH2), 7.11 (1 H, dd, J = 
8.2, 2.2 Hz, Ar 6-H), 7.36 (1 H, d, J = 2.2 Hz, Ar 2-H), 7.62 (1 H, d, J = 8.2 Hz, Ar 5-H); 
NMR ((CD3)2SO) δC 25.87, 28.50, 32.70, 34.64, 61.02, 105.23, 130.21, 131.37, 131.74, 
131.81, 133.19, 137.66, 162.36, 162.69, 165.96; MS m/z 345.0885 (M + H) (C15H1937Cl2N4O 
requires 345.0876), 343.0901 (M + H) (C15H1937Cl35ClN4O requires 343.0906), 341.0927 (M 
+ H) (C15H1935Cl2N4O requires 341.0935), 285/283/281 (M - C3H7O), 272/270/268 (M – 
C4H8O). 
6.18. 5-Phenyl-6-((1S,2R)-1,2,3-trihydroxypropyl)pyrimidine-2,4-diamine (10a) 
Compound 52a was treated with aq. CF3CO2H, as for the synthesis of 26a (reaction time 2 h), 
to give 10a (73%) as a highly hygroscopic white solid: [α]20D = -0.38° (c 4, MeOH); NMR 
(CD3CN) δH 3.45 (1 H, dd, J = 11.6, 4.9 Hz, 3’-H), 3.48 (1 H, dd, J = 11.6, 3.9 Hz, 3’-H), 
3.72 (1 H, m, 2’-H), 4.46 (1 H, d, J = 6.2 Hz, 1’-H), 4.73 (2 H, br, NH2), 5.82 (1 H, br, NH), 
6.98 (1 H, br, NH), 7.31 (2 H, dd, J = 7.4, 2.0 Hz, Ph 2,6-H2), 7.45-7.61 (3 H, m, Ph 3,4,5-
H3); MS m/z 299 (M + Na), 277.1308 (M + H) (C13H17N4O3 requires 277.1300). 
6.19. 5-(4-Chlorophenyl)-6-((1S,2R)-1,2,3-trihydroxypropyl)pyrimidine-2,4-diamine 
(10b) 
Compound 52b was treated with aq. CF3CO2H, as for the synthesis of 26a, to give 10b (90%) 
as a pale yellow solid: mp 196-197 ºC; [α]20D = -41° (c 0.4, MeOH); IR νmax 3550, 3475, 
3413, 1617 cm-1; NMR ((CD3)2SO) δH 3.58 (1 H, dd, J = 11.3, 4.7 Hz, 3’-H, 3.63 (1 H, dd, J 
= 11.3, 3.5 Hz, 3’-H), 3.89-3.92 (1 H, m, 2’-H), 4.54 (1H, d, J = 7.0 Hz, 1’-H), 5.54 (5 H, br) 
and, 6.62 (1 H, br) (2 × NH2 + 2 × OH), 7.40 (2 H, d, J = 7.4 Hz, Ar 2,6-H2), 7.47 (2 H, d, J = 
7.4 Hz, Ar 3,5-H2),7.79 (1 H, br, OH); NMR ((CD3)2SO) δC 62.60, 69.31, 72.47, 108.42, 
129.88, 132.39, 133.53, 134.72, 161.21, 161.53, 161.87; MS m/z 313.0877 (M + H) 
(C13H1637ClN4O3 requires 313.0881), 311.0905 (M + H) (C13H1635ClN4O3 requires 311.0910). 
6.20. 5-(4-Bromophenyl)-6-((1S,2R)-1,2,3-trihydroxypropyl)pyrimidine-2,4-diamine 
(10c) 
Compound 52c was treated with aq. CF3CO2H, as for the synthesis of 26a (reaction time 4 h), 
to give 10c (95%) as a highly hygroscopic pale yellow solid: [α]20 D = -15° (c 0.9, MeOH); IR 
νmax 3550, 3478, 3414, 1618 cm-1; NMR (CD3CN) δH 3.51 (1 H, dd, J = 12.3, 4.9 Hz, 3’-H), 
3.55 (1 H, dd, J = 12.3, 4.5 Hz, 3’-H), 3.74 (1 H, m, 2’-H), 4.49 (1 H, d, J = 6.2 Hz, 1’-H), 
5.94 (2 H, br, NH2), 7.03 (2 H, br, NH2), 7.29 (2 H, d, J = 8.0 Hz, Ar 2,6-H2), 7.71 (2 H, d, J 
= 8.0 Hz, Ar 3,5-H2); NMR (CD3CN) δC 62.47, 68.98, 72.30, 108.83, 123.37, 129.70, 132.92, 
132.98, 133.81, 156.05, 162.06, 164.91; MS m/z 379/377 (M + Na), 357.0396 (M + H) 
(C13H1681BrN4O3 requires 357.0385), 355.0412 (M + H) (C13H1679BrN4O3 requires 355.0405). 
6.21. 5-(3,4-Dichlorophenyl)-6-((1S,2R)-1,2,3-trihydroxypropyl)pyrimidine-2,4-diamine 
(10d) 
Compound 52d was treated with aq. CF3CO2H, as for the synthesis of 10c, to give 10d (87%) 
as a pale yellow solid: mp 120-121 ºC; [α]20D = -3.0° (c 4.7, MeOH); IR νmax 3549, 3476, 
3415, 1618 cm-1; NMR (CD3CN) δH 3.41 (1 H, d, J = 13.1 Hz, 3’-H), 3.45 (1 H, d, J = 13.1 
Hz, 3’-H), 3.63-3.68 (1 H, m, 2’-H), 4.35 (1 H, d, J = 4.7 Hz, 1’-H), 5.25 (2 H, br, NH2), 5.67 
(2 H, br, NH2), 7.20 (1 H, dd, J = 8.0, 1.9 Hz, Ar 6-H), 7.46 (1 H, d, J = 1.9 Hz, Ar 2-H), 7.60 
(1 H, d, J = 8.0 Hz, Ar 5-H); NMR ((CD3)2SO) δC 63.67, 69.38, 74.29, 106.16, 130.30, 
131.08, 131.44, 131.63, 132.68, 134.09, 162.01, 162.81, 164.00; MS m/z 371/369/367 (M + 
Na), 349.0469 (M + H) (C13H1537Cl2N4O3 requires 349.0462), 347.0501 (M + H) 
(C13H1537Cl35ClN4O3 requires 347.0491), 345.0521 (M + H) (C13H1535Cl2N4O3 requires 
345.0521). 
6.22. 1-Cyano-1,4-diphenyl-2-methoxybut-1-ene (56) and 5-phenyl-6-(2-phenylethyl)-
pyrimidine-2,4-diamine (11) 
Compound 54/55 was treated with CH2N2, as for the synthesis of 24a, to give 56 (95%) as a 
pale yellow oil: IR νmax 2204 cm-1; MS m/z 264.1390 (M + H) (C18H18NO requires 264.1388), 
236 (M – HCN), 91 (Bn). Compound 56 was treated with guanidine, as for the synthesis of 
25a (chromatographic eluant CH2Cl2 / MeOH (8:1)), to give 11 (32%) as a pale yellow solid: 
mp 116-118ºC; NMR δH 2.54 (2 H, t, J = 8.0 Hz, CH2), 2.83 (2 H, t, J = 8.0 Hz, CH2), 4.62 (2 
H, br, NH2), 4.99 (2 H, br, NH2), 6.94 (2 H, d, J = 6.8 Hz, Ph 2,6-H2), 7.05 (2 H, d, J = 6.5 
Hz, Ph’ 2,6-H2), 7.14 (1H, t, J = 6.8 Hz, Ph 4-H), 7.17 (2 H, t, J = 6.8 Hz, Ph 3,5-H2) 7.35 (2 
H, t, J = 6.5 Hz, Ph’ 4-H), 7.39 (2 H, t, J = 6.5 Hz, Ph’ 3,5-H2); MS m/z 291.1616 (M + H) 
(C18H19N4 requires 291.1609), 199 (M – Bn). 
6.23. 1-Cyano-2-methoxy-1-phenylprop-1-ene (60) and 6-methyl-5-phenylpyrimidine-
2,4-diamine (12) 
Compound 58/59 was treated with CH2N2, as for the synthesis of 24a, to give 60 (87%) as a 
pale yellow oil: IR νmax 2204, 1606 cm-1; NMR δH 2.45 (3 H, s, CMe), 3.85 (3 H, s, OMe), 
7.26 (1 H, t, J  = 7.0 Hz, Ph 4-H), 7.30 (2 H, t, J = 7.0 Hz, Ph 3,5-H2), 7.61 (2 H, t, J = 7.0 Hz, 
Ph 2,6-H2); MS m/z 174.0921 (M + H) (C11H12NO requires 174.0918). Compound 60 was 
treated with guanidine, as for the synthesis of 25a (chromatographic eluant CH2Cl2 / MeOH 
(4:1)), to give 12 (38%) as a pale yellow solid: mp 250-251ºC (lit.19 mp 249-251ºC); IR νmax 
3395, 3323 cm-1; NMR ((CD3)2SO) δH 1.85 (3 H, s, Me), 5.62 (2 H, br, NH2), 6.00 (2 H, br, 
NH2), 7.20 (2 H, d, J = 7.3 Hz, Ph 2,6-H2), 7.33 (1 H, t, J = 7.3 Hz, Ph 4-H), 7.43 (2 H, t, J = 
7.3 Hz, Ph 3,5-H2); MS m/z 201.1145 (M + H) (C11H13N4 requires 201.1140), 123 (M – 
C6H5), 109 (M – C7H7). 
6.24. 2,3-O-Isopropylidene-L-erythrose (18) 
L-Arabinose 17 (10.0 g, 67 mmol), TsOH.H2O (150 mg, 0.79 mmol) and 2,2-dimethoxy-
propane (23.0 g, 221 mol) were stirred in dry DMF (130 mL) under N2 for 90 min. The 
mixture was neutralised with Na2CO3. The evaporation residue was added to water (120 mL) 
and hexane (60 mL). NaIO4 (35.5 g, 0.17 mol) was added to the aq. layer and the mixture was 
stirred for 2 h. Na2CO3 was added and the slurry was stirred for 1 h. The mixture was 
extracted with EtOAc. Evaporation and chromatography (Et2O / hexane 2:1) gave 18 (5.8 g, 
54%) as a colourless oil (lit.45 oil): NMR δH 1.31 (3 H, s, Me), 1.46 (3 H, s, Me), 3.89 (1 H, d, 
J = 2.5 Hz, OH), 4.01 (1 H, d, J = 10.5 Hz, 4-H), 4.05 (1 H, dd, J =10.5, 3.5 Hz, 4-H), 4.55 (1 
H, d, J = 6.0 Hz, 2-H), 4.82 (1 H, dd, J = 6.0, 3.5 Hz, 3-H), 5.39 (1 H, d, J = 2.5 Hz, 1-H); MS 
m/z 181 (M + Na), 159.0650 (M - H) (C7H11O4 requires 159.0657). 
6.25. Ethyl (Z,4S,5R)-4-hydroxymethyl-2,2-dimethyl-1,3-dioxolane-5-propenoate (19Z) 
and ethyl (E,4S,5R)-4-hydroxymethyl-2,2-dimethyl-1,3-dioxolane-5-propenoate (19E) 
Ethyl triphenylphosphoranylidineacetate (9.3 g, 27 mmol) was stirred with 18 (2.9 g, 18 
mmol) in CH2Cl2 (130 mL) for 16 h. The evaporation residue was extracted with Et2O. Evap-
oration and chromatography (Et2O / hexane 1:1) gave 19Z (2.2 g, 54%) as a colourless oil 
(lit.46 oil): NMR δH 1.29 (3 H, t, J = 7.0 Hz, CH2CH3), 1.40 (3 H, s, 2-Me), 1.53 (3 H, s, 2-
Me), 2.44 (1 H, dd, J = 7.4, 5.5 Hz, OH), 3.45 (1 H, m, CHHOH), 3.59 (1 H, m, CHHOH), 
4.16 (2 H, q, J = 7.4 Hz, CH2CH3), 4.53-4.57 (1 H, m, 4-H), 5.58 (1 H, dt, J = 7.1, 1.7 Hz, 5-
H), 5.91 (1 H, dd, J = 11.7, 1.7 Hz, CHCO2), 6.36 (1 H, dd, J = 11.7, 7.1 Hz, CH=CCO2). 
Further elution gave 19E (600 mg, 15%) as a colourless oil (lit.46 oil): NMR δH 1.29 (3 H, t, J 
= 7.2 Hz, CH2CH3), 1.40 (3 H, s, 2-Me), 1.52 (3 H, s, 2-Me), 2.41 (1 H, t, J = 5.9 Hz, OH), 
3.55 (2 H, t, J = 5.9 Hz, CH2OH), 4.18 (2 H, q, J = 7.2 Hz, CH2CH3), 4.35 (1 H, m, 4-H), 4.79 
(1H, dt, J = 5.5, 1.6 Hz, 5-H), 6.12 (1 H, dd, J = 15.6, 1.6 Hz, CHCO2), 6.88 (1 H, dd, J = 
15.6, 5.5 Hz, CH=CCO2); MS m/z 231.1240 (M + H) (C11H19O5 requires 231.1232), 215 (M - 
CH3), 173 (M – C3H5O), 143 (M – C4H7O2). 
6.26. Ethyl (4S,5R)-4-hydroxymethyl-2,3-dimethyl-1,3-dioxolane-5-propanoate (20) 
A mixture of 19Z and 19E (2.3 g, 10 mmol) was stirred in EtOH (100 mL) with Pd/C (5%, 
150 mg) under H2 for 3 h. Filtration (Celite®) and evaporation gave 20 (2.3 g, 99%) as a pale 
yellow oil (lit.46 oil): NMR δH 1.26 (3 H, t, J = 7.0 Hz, CH2CH3), 1.33 (3 H, s, 2-Me), 1.42 (3 
H, s, 2-Me), 1.82 (2 H, m, CH2CH2CO2), 2.39 (1 H, br, OH), 2.40 (1 H, dt, J = 16.4, 7.8 Hz, 
CHCO2), 2.53 (1 H, dt, J = 16.4, 7.4 Hz, CHCO2), 3.65 (2 H, d, J = 5.1 Hz, CH2OH), 4.09-
4.20 (4 H, m, 4-H + 5-H + CH2CH3); MS m/z 233.1396 (M + H) (C11H19O5 requires 
233.1388), 217 (M - CH3). 
6.27. Ethyl (4S,5R)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-4-propanoate (21) 
LiN(SiMe3)2 (1.0 M in THF, 10 mL, 10 mmol) was stirred with 20 (2.3 g, 10 mmol) and 
BnBr (3.4 g, 20 mmol) in dry DMF (5 mL). After 2 h, water was added. The mixture was ex-
tracted (Et2O). The extract was washed with water and brine and was dried. Evaporation and 
chromatography (Et2O / hexane 1:4) afforded 21 (1.6 g, 48%) as a pale yellow oil: [α]20D = 
+24.8° (c 4.4, CHCl3); NMR δH 1.24 (3 H, t, J = 7.0 Hz, CH2CH3), 1.33 (3 H, s, 2-Me), 1.42 
(3 H, s, 2-Me), 1.72-1.86 (2 H, m, CH2CH2CO2), 2.50 (1 H, m, CHCO2), 2.48-2.54 (1 H, m, 
CHCO2), 3.50 (2 H, m, CH2OBn), 4.08-4.15 (3 H, m, 5-H + CH2CH3), 4.28 (1 H, dd, J = 
11.9, 6.1 Hz, 4-H), 4.50 (1 H, d, J = 12.1 Hz, CHPh), 4.57 (1 H, d, J = 12.1 Hz, CHPh), 7.24-
7.33 (5H, m, Ph-H5); MS m/z 323.1864 (M + H) (C18H27O5 requires 323.1858), 265 (M – 
C3H5O), 91 (Bn). 
6.28. (4R,5S)-5-Benzyloxymethyl-4-(4-cyano-3-oxo-4-phenylbutyl)-2,2-dimethyl-1,3-diox-
olane (22a) / (4R,5S)-5-benzyloxymethyl-4-(4-cyano-3-hydroxy-4-phenylbut-3-enyl)-2,2-
dimethyl-1,3-dioxolane (23a) 
LiN(SiMe3)2 (1.0 M in THF, 9.1 mL, 9.1 mmol) was added to phenylacetonitrile (1.1 g, 9.4 
mmol) in dry Et2O (10 mL) under N2 at -78°C. After 10 min, 21 (2.9 g, 9.0 mmol) was added. 
The mixture was allowed to warm to 20°C and was stirred for 72 h. Water was added. The 
solution was washed twice (Et2O) before being acidified to pH 6 with aq. citric acid (1 M) in 
the presence of EtOAc. The EtOAc phase was separated and washed with water. Drying, 
evaporation and chromatography (EtOAc / hexane, 2:1) gave 22a/23a (1.5 g, 21%) as a 
yellow oil: IR νmax 2207, 1728 cm-1; NMR δH 1.26 (3 H, s, 2-Me), 1.34 (3 H, s, 2-Me), 1.66-
1.80 (2 H, m, CH2CH2CO), 2.63 (1 H, m, CHCO), 2.75-2.80 (1 H, m, CHCO), 3.45 (2 H, d, J 
= 6.0 Hz, CH2OBn), 3.98 (1 H, m, 4-H), 4.20 (1 H, q, J = 6.0 Hz, 5-H), 4.45 (1 H, d, J = 11.5 
Hz, CHPh), 4.52 (1 H, d, J = 11.5 Hz, CHPh), 7.21-7.41 (10 H, m, 2 × Ph-H5), 8.98 (1 H, s, 
OH); MS m/z 394.2016 (M + H) (C24H28NO4 requires 394.2018), 91 (Bn). 
6.29. (4R,5S)-5-Benzyloxymethyl-4-(4-(4-chlorophenyl)-4-cyano-3-oxobutyl)-2,2-dimeth-
yl-1,3-dioxolane (22b) / (4R,5S)-5-benzyloxymethyl-4-(4-cyano-3-hydroxy-4-(4-chloro-
phenyl)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (23b) 
4-Chlorophenylacetonitrile and 21 were condensed as for the synthesis of 22a/23a (chromato-
graphic eluant EtOAc / hexane (1:1)), to give 22b/23b (26%) as a yellow oil: NMR δH 1.25 
(2.7 H, s, Me), 1.34 (2.7 H, s, Me), 1.40 (0.3 H, s, Me), 1.51 (0.3 H, s, Me), 1.67-1.88 (2 H, 
m, CH2CH2CO), 1.98-2.08 (0.2 H, m, CH2CO), 2.60-2.80 (1.8 H, m, CH2CO), 3.45 (1 H, dd, 
J = 12.1, 6.0 Hz, CHOBn), 3.47 (1 H, dd, J = 12.1, 6.0 Hz, CHOBn), 4.00 (0.9 H, ddd, J = 
8.6, 6.0, 2.3 Hz, 4-H), 4.22 (0.9 H, q, J = 6.0 Hz, 5-H), 4.29 (0.1 H, ddd, J = 10.14, 6.0, 3.9 
Hz, 4-H), 4.39 (0.1 H, q, J = 6.0 Hz, 5-H), 4.45 (0.1 H, d, J = 11.5 Hz, CHPh), 4.49 (0.1 H, d, 
J = 11.5 Hz, CHPh), 4.51 (0.9 H, d, J = 11.9 Hz, CHPh), 4.56 (0.9 H, d, J = 11.9 Hz, CHPh), 
5.52 (0.1 H, s, CHCN), 7.16 (0.2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.25-7.32 (5 H, m, Ph-H5), 7.35 
(1.8 H, d, J = 8.6 Hz, Ar 3,5-H2), 7.84 (1.8 H, d, J = 8.6 Hz, Ar 2,6-H2), 9.33 (0.9 H, br, OH); 
MS m/z 430.1604 (M + H) (C24H2637ClNO4 requires 430.1599), 428.1618 (M + H) 
(C24H2735ClNO4 requires 428.1628), 370 (M - C2H4NO), 91 (Bn). 
6.30. (4R,5S)-5-Benzyloxymethyl-4-(4-(4-bromophenyl)-4-cyano-3-oxobutyl)-2,2-dimeth-
yl-1,3-dioxolane (22c) / (4R,5S)-5-benzyloxymethyl-4-(4-cyano-3-hydroxy-4-(4-bromo-
phenyl)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (23c) 
4-Bromophenylacetonitrile and 21 were condensed, as for the synthesis of 22a/23a, to give 
22c/23c (18%) as a pale yellow oil: NMR δH 1.27 (3 H, s, 2-Me), 1.35 (3 H, s, 2-Me), 1.70-
1.82 (2H, m, CH2CHO), 2.62-2.78 (2 H, m, CH2C=O), 3.45-3.47 (2 H, m, CH2OBn), 4.00 (1 
H, ddd, J = 10.1, 6.2, 3.9 Hz, 4-H), 4.22 (1 H, q, J = 6.2 Hz, 5-H), 4.45 (1 H, d, J = 11.9 Hz, 
CHPh), 4.49 (1 H, d, J = 11.9 Hz, CHPh), 5.48 (0.35 H, s, CHCN), 7.21-7.35 (5 H, m, Ph-H5), 
7.45 (1.3 H, d, J = 8.8 Hz, Ar 2,6-H2), 7.55 (1.3 H, d, J = 8.8 Hz, Ar 3,5-H2), 7.59 (0.7 H, d, J 
= 8.6 Hz, Ar 3,5-H2), 7.76 (0.7 H, d, J = 8.6 Hz, Ar 2,6-H2), 9.35 (0.65 H, s, OH); MS m/z 
474.1100 (M + H) (C24H2781BrNO4 requires 474.1102), 472.1094 (M + H) (C24H2779BrNO4 
requires 472.1123), 415/413 (M - C2H4NO), 91 (Bn). 
6.31. (4R,5S)-5-Benzyloxymethyl-4-(4-(3,4-dichlorophenyl)-4-cyano-3-oxobutyl)-2,2-di-
methyl-1,3-dioxolane (22d) / (4R,5S)-5-benzyloxymethyl-4-(4-cyano-3-hydroxy-4-(3,4-di-
chlorophenyl)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (23d) 
3,4-Dichlorophenylacetonitrile and 21 were condensed, as for the synthesis of 22a/23a, to 
give 22d/23d (16%) as a highly hygroscopic white solid: NMR δH 1.41 (3 H, s, 2-Me), 1.52 (3 
H, s, 2-Me), 1.73-1.87 (2 H, m, CH2CHO), 2.71-2.84 (2 H, m, CH2C=O), 3.47 (1 H, dd, J = 
11.7, 6.0 Hz, CHOBn), 3.49 (1 H, dd, J = 11.7, 6.0 Hz, CHOBn), 3.98 (1 H, m, 4-H), 4.22 (1 
H, q, J = 6.0 Hz, 5-H), 4.47 (1 H, d, J = 12.3 Hz, CHPh), 4.56 (1 H, d, J = 12.3 Hz, CHPh), 
7.26-7.37 (5 H, m, Ph-H5), 7.45 (1 H, d, J = 8.6 Hz, Ar 5-H), 7.50 (1 H, dd, J = 8.6, 2.0 Hz, 
Ar 6-H), 7.83 (1 H, d, J = 2.0 Hz, Ar 2-H), 9.61 (1 H, s, OH); MS m/z. 466.1178 (M + H) 
(C24H2637Cl2NO4 requires 466.1179), 464.1193 (M + H) (C24H2637Cl35ClNO4 requires 
464.1209), 462.1217 (M + H) (C24H2635Cl2NO4 requires 462.1238), 407/405/403 (M - 
C2H4NO), 91 (Bn). 
6.32. (4R,5S)-5-Benzyloxymethyl-4-(4-cyano-3-methoxy-4-phenylbut-3-enyl)-2,2-dimeth-
yl-1,3-dioxolane (24a) and 6-(2-((4R,5S)-5-benzyloxymethyl-2,2-dimethyl-1,3-dioxolan-4-
yl)ethyl)-5-phenylpyrimidine-2,4-diamine (25a) 
Compound 22a/23a (1.5 g, 3.7 mmol) in THF (5 mL) was treated with CH2N2 (8.0 mmol) in 
Et2O (20 mL) at 10°C for 16 h. Excess CH2N2 was destroyed by careful addition of AcOH 
(30% in THF). Evaporation gave 24a (1.2 g, 81%) as a yellow oil: NMR δH 1.37 (3 H, s, 2-
Me), 1.46 (3 H, s, 2-Me), 1.77-1.88 (2 H, m, CH2CHO), 2.78-2.86 (1 H, m, CHC=C), 2.90-
2.98 (1 H, m, CHC=C), 3.53 (2 H, d, J = 5.9 Hz, CH2OBn), 3.78 (3 H, s, OMe), 4.22 (1 H, m, 
4-H), 4.33 (1 H, m, 5-H), 4.51 (1 H, d, J = 12.1 Hz, CHPh), 4.59 (1 H, d, J = 12.1 Hz, CHPh), 
7.21-7.59 (10 H, m, 2 × Ph-H5); MS m/z 408.2166 (M + H) (C25H30NO4 requires 408.2174), 
350 (M – C2H3NO), 91 (Bn). NaOMe (140 g, 2.6 mmol) was stirred with guanidine.HCl (300 
mg, 2.6 mmol) in MeO(CH2)2OH (10 mL) stirred for 5 min at 30°C. The filtered solution was 
boiled under reflux with 24a (700 mg, 1.8 mmol) for 16 h. Evaporation and chromatography 
(CHCl3 / MeOH 19:1) gave 25a (400 mg, 46%) as a highly hygroscopic pale yellow solid: IR 
νmax 3415, 1685 cm-1; NMR δH 1.23 (3 H, s, Me), 1.24 (3 H, s, Me), 1.61-1.67 (2 H, m, 
CH2CHO), 2.24 (1 H, m, Pyr-CH), 2.51 (1 H, m, Pyr-CH), 3.4 (2 H, d, J = 6.0 Hz, CH2OBn), 
3.95-4.00 (1 H, m, dioxolane 4-H), 4.15 (1 H, q, J = 6.0 Hz, dioxolane 5-H), 4.44 (1H, d, J = 
12.3 Hz, CHPh), 4.53 (1 H, d, J = 12.3 Hz, CHPh), 4.68 (2 H, br, NH2), 5.01 (2 H, br, NH2), 
7.09-7.39 (10H, m, 2 × Ph-H5); MS m/z 435.2423 (M + H) (C25H31N4O3 requires 435.2396), 
200 (M – C14H18O3), 91 (Bn). 
6.33. (4R,5S)-5-Benzyloxymethyl-4-(-4-(4-chlorophenyl)-4-cyano-3-methoxybut-3-enyl)-
2,2-dimethyl-1,3-dioxolane (24b) and 6-(2-((4R,5S)-5-benzyloxymethyl-2,2-dimethyl-1,3-
dioxolan-4-yl)ethyl)-5-(4-chlorophenyl)pyrimidine-2,4-diamine (25b) 
Compound 22b/23b was treated with CH2N2, as for the synthesis of 24a, to give 24b (97%) as 
a pale yellow oil: NMR δH 1.36 (3 H, s, 2-Me), 1.45 (3 H, s, 2-Me), 1.74 (1 H, m, CHCHO), 
1.85 (1 H, m, CHCHO), 2.80 (1 H, m, CHC=C), 2.94 (1 H, m, CHC=C), 3.51 (1 H, dd, J = 
11.7, 6.0 Hz, CHOBn), 3.53 (1 H, dd, J = 11.7, 6.0 Hz, CHOBn), 3.80 (3 H, s, OMe), 4.22 (1 
H, ddd, J = 9.4, 6.0, 3.1 Hz, 4-H), 4.33 (1 H, q, J = 6.0 Hz, 5-H), 4.50 (1 H, d, J = 12.1 Hz, 
CHPh), 4.59 (1 H, d, J = 12.1 Hz, CHPh), 7.28 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.30-7.36 (5 
H, m, Ph-H5), 7.52 (2 H, d, J = 8.6 Hz, Ar 3,5-H2); MS m/z 444.1746 (M + H) 
(C25H2937ClNO4 requires 444.1755), 442.1764 (M + H) (C25H2935ClNO4 requires 442.1785), 
428/426 (M - CH3), 386/384 (M – C2H3NO), 91 (Bn). Compound 24b was treated with 
guanidine, as for the synthesis of 25a (chromatographic eluant CHCl3 / MeOH (9:1)) to give 
25b (25%) as a pale buff solid: mp 55-56°C; NMR δH 1.28 (6 H, s, Me2), 1.62-1.71 (2 H, m, 
CH2CHO), 2.25 (1 H, ddd, J = 13.5, 10.1, 5.9 Hz, Pyr-CH), 2.51 (1 H, ddd, J = 13.5, 10.1, 5.9 
Hz, Pyr-CH), 3.43 (2 H, d, J = 5.9 Hz, CH2OBn), 4.01 (1 H, ddd, J = 10.1, 5.9, 4.3 Hz, 
dioxolane 4-H), 4.21 (1 H, q, J = 5.9 Hz, dioxolane 5-H), 4.47 (1 H, d, J = 12.1 Hz, CHPh), 
4.56 (1 H, d, J = 12.1 Hz, CHPh), 4.82 (2 H, br, NH2), 5.23 (2 H, br, NH2), 7.14 (1 H, d, J = 
8.2 Hz, Ar 2-H), 7.15 (1 H, d, J = 8.2 Hz, Ar 6-H), 7.27-7.37 (5H, m, Ph-H5), 7.39 (2 H, d, J = 
8.2 Hz, Ar 3,5-H2); MS m/z 471.1992 (M + H) (C25H3037ClN4O3 requires 471.1976), 469.2005 
(M + H) (C25H3035ClN4O4 requires 469.2006), 236/234 (M – C14H18O3), 91 (Bn). 
6.34. (4R,5S)-5-Benzyloxymethyl-4-(4-(4-bromophenyl)-4-cyano-3-methoxybut-3-enyl)-
2,2-dimethyl-1,3-dioxolane (24c) and 6-(2-((4R,5S)-5-benzyloxymethyl-2,2-dimethyl-1,3-
dioxolan-4-yl)ethyl)-5-(4-bromophenyl)pyrimidine-2,4-diamine (25c) 
Compound 22c/23c was treated with CH2N2, as for the synthesis of 24a, to give 24c (87%) as 
a pale yellow oil: NMR δH 1.36 (3 H, s, 2-Me), 1.45 (3 H, s, 2-Me), 1.75-1.88 (2 H, m, 
CH2CHO), 2.80 (1 H, m, CHC=C), 2.93 (1 H, m, CHC=C), 3.51 (1 H, dd, J = 11.7, 5.9 Hz, 
CH2OBn), 3.53 (1 H, dd, J = 11.7, 5.9 Hz, CH2OBn), 3.80 (3 H, s, OMe), 4.21 (1 H, ddd, J = 
9.4, 5.9, 3.1 Hz, 4-H), 4.32 (1 H, q, J = 5.9 Hz, 5-H), 4.50 (1 H, d, J = 11.9 Hz, CHPh), 4.59 
(1 H, d, J = 11.9 Hz, CHPh), 7.27-7.32 (5H, m, Ph-H5), 7.43 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 
7.47 (2 H, d, J = 9.0 Hz, Ar 3,5-H2); MS m/z 488.1255 (M + H) (C25H2981BrNO4 requires 
488.1259), 486.1263 (M + H) (C25H2979BrNO4 requires 486.1279), 430/428 (M - C2H3NO), 
91 (Bn). Compound 24c was treated with guanidine, as for the synthesis of 25a, to give 25c 
(57%) as a pale buff solid: mp 62-64°C; IR νmax 3462, 1635 cm-1; NMR δH 1.26 (6 H, s, Me2), 
1.58-1.63 (2 H, m, CH2CHO), 2.22 (1 H, ddd, J = 13.3, 10.1, 5.9 Hz, Pyr-CH), 2.49 (1 H, 
ddd, J = 13.3, 10.1, 5.9 Hz, Pyr-CH), 3.41 (2 H, d, J = 5.9 Hz, CH2OBn), 4.00 (1 H, ddd, J = 
9.8, 5.9, 3.5 Hz, dioxolane 4-H), 4.20 (1 H, q, J = 5.9 Hz, dioxolane 5-H), 4.45 (1 H, d, J = 
12.1 Hz, CHPh), 4.54 (1 H, d, J = 12.1 Hz, CHPh), 4.65 (2 H, br, NH2), 5.06 (2 H, br, NH2), 
7.04 (1 H, d, J = 7.8 Hz, Ar 2-H), 7.06 (1 H, d, J = 8.2 Hz, Ar 6-H), 7.23-7.33 (5 H, m, Ph-
H5), 7.50 (2 H, d, J = 8.2 Hz, Ar 3,5-H2); MS m/z 515.1483 (M + H) (C25H3081BrN4O3 
requires 515.1480), 513.1497 (M + H) (C25H3079BrN4O3 requires 513.1501), 499/497 (M – 
CH3), 91 (Bn). 
6.35. (4R,5S)-5-Benzyloxymethyl-4-(4-(3,4-dichlorophenyl)-4-cyano-3-methoxybut-3-en-
yl)-2,2-dimethyl-1,3-dioxolane (24d) and 6-(2-((4R,5S)-5-benzyloxymethyl-2,2-dimethyl-
1,3-dioxolan-4-yl)ethyl)-5-(3,4-dichlorophenyl)pyrimidine-2,4-diamine (25d) 
Compound 22d/23d was treated with CH2N2, as for the synthesis of 24a, to give 24d (97%) as 
a pale yellow oil: NMR δH 1.36 (3 H, s, 2-Me), 1.45 (3 H, s, 2-Me), 1.77 (1 H, m, CHCHO), 
1.85 (1 H, m, CHCHO), 2.81 (1 H, m, CHC=C), 2.94 (1 H, m, CHC=C), 3.51 (1 H, dd, J = 
11.3, 6.0 Hz, CHOBn), 3.53 (1 H, dd, J = 11.3, 6.0 Hz, CHOBn), 3.84 (3 H, s, OMe), 4.21 (1 
H, ddd, J = 9.4, 6.0, 3.1 Hz, 4-H), 4.32 (1 H, q, J = 6.0 Hz, 5-H), 4.49 (1 H, d, J = 12.1 Hz, 
CHPh), 4.58 (1 H, d, J = 12.1 Hz, CHPh), 7.26-7.32 (5H, m, Ph-H5), 7.37 (1 H, d, J = 8.6 Hz, 
Ar 5-H), 7.42 (1 H, dd, J = 8.6, 2.1 Hz, Ar 6-H), 7.73 (1 H, d, J = 2.1 Hz, Ar 2-H); MS m/z 
480.1319 (M + H) (C25H2837Cl2NO4 requires 480.1336), 478.1344 (M + H) (C25H2837Cl 
35ClNO4 requires 478.1365), 476.1367 (M + H) (C25H2835Cl2NO4 requires 476.1395), 
422/420/418 (M - C2H3NO), 91 (Bn). Compound 24d was treated with guanidine, as for the 
synthesis of 25a, to give 25d (47%) as a pale buff solid: mp 67-69°C; IR νmax 3411, 1637 cm-
1; NMR δH 1.27 (6 H, s, Me2), 1.60 (1 H, m, CHCHO), 1.73 (1 H, m, CHCHO), 2.25 (1 H, m, 
Pyr-CH), 2.47 (1 H, m, Pyr-CH), 3.44 (2 H, d, J = 6.0 Hz, CH2OBn), 3.99 (1 H, ddd, J = 9.8, 
6.0, 3.5 Hz, dioxolane 4-H), 4.20 (1 H, q, J = 6.0 Hz, dioxolane 5-H), 4.47 (1 H, d, J = 12.3 
Hz, CHPh), 4.56 (1 H, d, J = 12.3 Hz, CHPh), 4.85 (2 H, br, NH2), 5.21 (2 H, br, NH2), 7.03 
(1 H, dd, J = 8.0, 2.0 Hz, Ar 6-H), 7.26-7.32 (5 H, m, Ph-H5), 7.35 (1 H, d, J = 2.0 Hz, Ar 2-
H), 7.46 (1 H, d, J = 8.0 Hz, Ar 5-H); MS m/z 507.1563 (M + H) (C25H2937Cl2N4O3 requires 
507.1557), 505.1586 (M + H) (C25H2937Cl 35ClN4O3 requires 505.1587), 503.1617 (M + H) 
(C25H2935Cl2N4O3 requires 503.1616), 91 (Bn). 
6.36. 6-((3R,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-phenylpyrimidine-2,4-diamine 
(26a) 
Compound 25a (700 mg, 1.6 mmol) was stirred for 16 h with aq. CF3CO2H (30%, 70 mL). 
Evaporation and chromatography (CHCl3 / MeOH 7:3) to give 26a (600 mg, 95%) as a highly 
hygroscopic pale yellow solid: NMR (CD3OD) δH 1.69 (1 H, m, 2’-H), 1.88 (1 H, m, 2’-H), 
2.43 (1 H, m, 1’-H), 2.60 (1 H, ddd, J = 15.3, 10.6, 5.5 Hz, 1’-H), 3.43-3.47 (2 H, m, 3’,4’-
H2), 3.49-3.56 (2 H, m, 5’-H2), 4.52 (1 H, d, J = 12.6 Hz, CHPh), 4.56 (1 H, d, J = 12.6 Hz, 
CHPh), 7.27-7.41 (6 H, m, 2 × Ph 3,4,5-H3), 7.47-7.58 (4 H, m, 2 × Ph 2,6-H2); MS m/z 417 
(M + Na), 395.2097 (M + H) (C22H27N4O3 requires 395.2083), 243 (M - C9H11O2), 213 (M – 
C10H13O3), 91 (Bn). 
6.37. 6-((3R,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-(3-chlorophenyl)pyrimidine-2,4-di-
amine (26b) 
Compound 25b was treated with aq. CF3CO2H, as for the synthesis of 25a, to give 26b (87%) 
as a white solid: mp 131-133°C; NMR (CD3OD) δH 1.64 (1 H, m, 2’-H), 1.82 (1 H, m, 2’-H), 
2.37 (1 H, m, 1’-H), 2.51 (1 H, m, 1’-H), 3.49-3.55 (2 H, m, 3’,4’-H2), 3.57-3.64 (2 H, m, 5’-
H2), 4.52 (1 H, d, J = 12.5 Hz, CHPh), 4.56 (1 H, d, J = 12.5 Hz, CHPh), 7.24 (2 H, d, J = 8.6 
Hz, Ar 2,6-H2), 7.33-7.37 (5 H, m, Ph-H5), 7.47 (2 H, d, J = 8.6 Hz, Ar 3,5-H2); NMR 
(CD3OD) δC 29.02, 30.84, 71.03, 71.61, 72.09, 72.99, 107.42, 121.01, 127.36, 127.58, 128.01, 
129.32, 132.16, 134.14, 138.10, 161.81, 162.16, 163.66; MS m/z 453/451 (M + Na), 431.1657 
(M + H) (C22H2637ClN4O3 requires 431.1663), 429.1680 (M + H) (C22H2635ClN4O4 requires 
429.1693), 279/277 (M - C9H11O2), 249/247 (M – C10H13O3), 91 (Bn). 
6.38. 6-((3R,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-(3-bromophenyl)pyrimidine-2,4-di-
amine (26c) 
Compound 25c was treated with aq. CF3CO2H, as for the synthesis of 25a, to give 26c (91%) 
as a highly hygroscopic pale buff solid: NMR δH 1.65-1.84 (2 H, m, 2’-H2), 2.35-2.55 (2 H, 
m, 1’-H2), 3.52-3.71 (4 H, m, 3’,4’,5’-H4), 4.49 (1 H, d, J = 12.1 Hz, CHPh), 4.54 (1 H, d, J = 
12.1 Hz, CHPh), 4.71 (2 H, br, NH2), 5.09 (2 H, br, NH2), 7.05 (2 H, d, J = 8.4 Hz, Ar 2,6-
H2), 7.24-7.34 (5 H, m, Ph-H5), 7.54 (2 H, d, J = 8.4 Hz, Ar 3,5-H2); MS m/z 497/495 (M + 
Na), 475.1184 (M + H) (C22H2681BrN4O3 requires 475.1167), 473.1179 (M + H) 
(C22H2679BrN4O4 requires 473.1188), 323/321 (M - C9H11O2), 293/291 (M – C10H13O3), 91 
(Bn). 
6.39. 6-((3R,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-(3,4-dichlorophenyl)pyrimidine-
2,4-diamine (26d) 
Compound 25d was treated with aq. CF3CO2H, as for the synthesis of 25a, to give 26d (74%) 
as a pale yellow solid: mp 123-125°C; NMR (CD3OD) δH 1.60 (1 H, m, 2’-H), 1.82 (1 H, m, 
2’-H), 2.31 (1 H, ddd, J = 14.2, 9.0, 5.9 Hz, 1’-H), 2.47 (1 H, ddd, J = 14.2, 9.0, 5.9 Hz, 1’-
H), 3.44-3.51 (2 H, m, 3’,4’-H2), 3.54-3.59 (2 H, m, 5’-H2), 4.47 (1 H, d, J = 14.1 Hz, CHPh), 
4.52 (1 H, d, J = 14.1 Hz, CHPh), 7.15 (1 H, dd, J = 8.2, 1.9 Hz, Ar 6-H), 7.22-7.33 (5 H, m, 
Ph-H5), 7.41 (1 H, d, J = 1.9 Hz, Ar 2-H), 7.57 (1 H, d, J = 8.2 Hz, Ar 5-H); NMR (CD3OD) 
δC 23.30, 30.97, 71.23, 71.58, 72.99, 106.22, 181.16, 127.31, 127.55, 127.99, 130.64, 131.15, 
131.95, 132.61, 134.54, 138.17, 162.09, 162.83, 163.16; MS m/z 489/487/485 (M + Na), 
467.1258 (M + H) (C22H2537Cl2N4O3 requires 467.1244), 465.1272 (M + H) (C22H2537Cl 
35ClN4O3 requires 465.1274), 463.1293 (M + H) (C22H2535Cl2N4O3 requires 463.1303), 
315/313/311 (M - C9H11O2), 91 (Bn). 
6.40. (4R,5S)-4-(4-Cyano-3-oxo-4-phenylbutyl)-5-hydroxymethyl-2,2-dimethyl-1,3-diox-
olane (27a) / (4R,5S)-4-(4-cyano-3-hydroxy-4-phenylbut-3-enyl)-5-hydroxymethyl-2,2-di-
methyl-1,3-dioxolane (28a) 
LiN(SiMe3)2 (1.0 M in THF, 30 mL, 30 mmol) was added to phenylacetonitrile (1.75 g, 15 
mmol) in dry Et2O (15 mL) under N2 at -78°C. After 10 min, 20 (3.5 g, 15 mmol) was added. 
The mixture was warmed to 20°C and was stirred for 72 h. Water was added. The solution 
was washed twice (Et2O) before being acidified to pH 6 with aq. citric acid (1 M) in the pres-
ence of EtOAc. The EtOAc phase was separated and washed with water. Drying, evaporation 
and chromatography (EtOAc / hexane, 3:1) gave 27a/28a (450 mg, 10%) as a pale yellow oil: 
NMR δH 1.30 (3 H, s, Me), 1.40 (3 H, s, Me), 1.74-1.81 (2 H, m, CH2CHO), 2.71 (1 H, m, 
CHC=O), 2.83 (1 H, m, CHC=O), 3.62 (2 H, d, J = 5.5 Hz, CH2OH), 4.07 (1 H, m, 4-H), 4.15 
(1 H, m, 5-H), 4.79 (1 H, s, CHCN), 7.36-7.50 (5 H, m, Ph-H5); MS m/z 303.1464 (M + H) 
(C17H21NO4 requires 303.1470), 287 (M - CH3), 271 (M - CH3O), 245 (M – C2H3NO). 
6.41. (4R,5S)-4-(4-(4-Chlorophenyl)-4-cyano-3-oxobutyl)-5-hydroxymethyl-2,2-dimethyl-
1,3-dioxolane (27b) / (4R,5S)-4-(4-(4-chlorophenyl)-4-cyano-3-hydroxybut-3-enyl)-5-hyd-
roxymethyl-2,2-dimethyl-1,3-dioxolane (28b) 
4-Chlorophenylacetonitrile was condensed with 20, as for the synthesis of 27a/28a, to give 
27b/28b (7%) as a pale yellow solid: mp 133-135°C; NMR δH 1.42 (3 H, s, Me), 1.52 (3 H, s, 
Me), 2.35-2.52 (2 H, m, CH2CHO), 2.66-2.84 (2 H, m, CH2C=O), 3.63 (1 H, dd, J = 12.7, 4.9 
Hz, CHOH), 3.73 (1 H, dd, J = 12.7, 4.9 Hz, CHOH), 4.21-4.28 (2 H, m, 4,5-H2), 7.35 (2 H, 
d, J = 9.0 Hz, Ar 2,6-H2), 7.44 (2 H, d, J = 9.0 Hz, Ar 3,5-H2); MS m/z 340 (M + H) 
C17H2037ClNO4, 338 (M + H) C17H2035ClNO4, 322/320 (M – OH), 308/306 (M - CH3O). 
6.42. ((4R,5S)-4-(4-(4-Bromophenyl)-4-cyano-3-oxobutyl)-5-hydroxymethyl-2,2-dimeth-
yl-1,3-dioxolane (27c) / (4R,5S)-4-(4-(4-bromophenyl)-4-cyano-3-hydroxybut-3-enyl)-5-
hydroxymethyl-2,2-dimethyl-1,3-dioxolane (28c) 
4-Bromophenylacetonitrile was condensed with 20, as for the synthesis of 27a/28a, to give 
27c/28c (6%) as a pale yellow solid: mp 128-130°C; NMR δH 1.41 (3 H, s, Me), 1.51 (3 H, s, 
Me), 2.39-2.48 (2 H, m, CH2CHO), 2.69-2.79 (2 H, m, CH2C=O), 3.62 (1 H, dd, J = 11.6, 5.3 
Hz, CHOH), 3.73 (1 H, dd, J = 11.6, 5.3 Hz, CHOH), 4.19-4.27 (2 H, m, 4,5-H2), 7.30 (2 H, 
d, J = 8.5 Hz, Ar 2,6-H2), 7.47 (2 H, d, J = 8.5 Hz, Ar 3,5-H2); MS m/z 382.0480 (M + H) 
(C17H2081BrNO4 requires 382.0476), 380.0475 (M + H) (C17H2079BrNO4 requires 380.0497), 
368/366 (M - CH3), 342/340 (M - C2H3N), 326/324 (M – C2H3NO). 
6.43. (4R,5S)-4-(4-Cyano-4-(3,4-dichlorophenyl)-3-oxobutyl)-5-hydroxymethyl-2,2-di-
methyl-1,3-dioxolane (27d) / (4R,5S)-4-(4-cyano-4-(3,4-dichlorophenyl)-3-hydroxybut-3-
enyl)-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane (28d) 
3,4-Dichlorophenylacetonitrile was condensed with 20, as for the synthesis of 27a/28a, to 
give 27d/28d (7%) as a pale yellow solid: mp 117-118 °C; IR νmax 3424, 2209, 1718 cm-1; 
NMR δH 1.42 (3 H, s, Me), 1.52 (3 H, s, Me), 2.38-2.47 (2 H, m, CH2CHO), 2.72-2.84 (2 H, 
m, CH2C=O), 3.64 (1 H, dd, J = 11.5, 5.5 Hz, CHOH), 3.75 (1 H, dd, J = 11.5, 5.5 Hz, 
CHOH), 4.18-4.29 (2 H, m, 4,5-H2), 7.27 (1 H, dd, J = 8.5, 2.2 Hz, Ar 6-H), 7.43 (1 H, d, J = 
8.5 Hz, Ar 5-H), 7.54 (1 H, d, J = 2.2 Hz, Ar 2-H). MS m/z 375/373/371 (M + H), 
334/332/330 (M - C2H2N), 316/314/312 (M – C2H3NO). 
6.44. (4R,5S)-4-(4-Cyano-3-methoxy-4-phenylbut-3-enyl)-2,2-dimethyl-5-hydroxymeth-
yl-1,3-dioxolane (29a) and 6-(2-((4R,5S)-2,2-dimethyl-5-hydroxymethyl-1,3-dioxolan-4-
yl)ethyl)-5-phenylpyrimidine-2,4-diamine (30a) 
Compound 27a/28a was treated with CH2N2, as for the synthesis of 24a, to give 29a (330 mg, 
95%) as a pale yellow oil: NMR δH 1.40 (3 H, s, 2-Me), 1.51 (3 H, s, 2-Me), 1.87-2.01 (2 H, 
m, CH2CHO), 2.84-3.02 (2 H, m, CH2C=C), 3.69 (2 H, d, J = 5.9 Hz, CH2OH), 3.86 (3 H, s, 
OMe), 4.22-4.27 (2 H, m, 4,5-H2), 7.24-7.42 (5 H, m, Ph-H5); MS m/z 318.1707 (M + H) 
(C18H24NO4 requires 318.1705), 302 (M – Me), 277 (M - C2H2N), 258 (M – C2H5NO). Comp-
ound 29a was treated with guanidine, as for the synthesis of 25a (reaction time 4 h, chromato-
graphic eluant CHCl3 / MeOH (9:1)), to give 30a (42%) as a pale buff solid: mp 72-75°C; 
NMR (D2O) δH 1.27 (3 H, s, Me), 1.31 (3 H, s, Me), 1.75-1.88 (2 H, m, CH2CHO), 2.32 (1 H, 
ddd, J = 15.9, 9.7, 6.0 Hz, Pyr-CH), 2.49 (1 H, ddd, J = 15.9, 8.7, 7.4 Hz, Pyr-CH), 3.53 (1 H, 
dd, J = 11.6, 5.9 Hz, CHOH), 3.65 (1 H, dd, J = 11.6, 5.9 Hz, CHOH), 4.05 (1 H, dd, J = 
12.2, 5.9 Hz, dioxolane 4-H), 4.12 (1 H, q, J = 5.9 Hz, dioxolane 5-H), 4.63 (2 H, br, NH2), 
4.95 (2 H, br, NH2), 7.21 (1 H, d, J = 7.9 Hz, Ar 2-H), 7.22 (1 H, d, J = 7.9 Hz, Ar 6-H), 7.36 
(1 H, t, J = 7.9 Hz, Ar 4-H), 7.21 (2H, t, J = 7.9 Hz, Ar 3,5-H2); NMR (D2O) δC 23.01, 25.58, 
25.70, 28.17, 58.60, 74.07, 75.63, 105.27, 106.26, 125.50, 126.82, 126.85, 127.94, 158.71, 
159.82, 162.92; MS m/z 345.1935 (M + H) (C19H24N4O3 requires 345.1926), 329 (M - Me), 
200 (M – C7H12O3). 
6.45. (4R,5S)-4-(4-(4-Chlorophenyl)-4-cyano-3-methoxybut-3-enyl)-2,2-dimethyl-5-hydr-
oxymethyl-1,3-dioxolane (29b) and 5-(4-chlorophenyl)-6-(2-((4R,5S)-2,2-dimethyl-5-hyd-
roxymethyl-1,3-dioxolan-4-yl)ethyl)pyrimidine-2,4-diamine (30b) 
Compound 27b/28b was treated with CH2N2, as for the synthesis of 24a, to give 29b (90%) as 
a pale yellow oil. Compound 29b was treated with guanidine, as for the synthesis of 25a 
(reaction time 10 h, chromatographic eluant CHCl3 / MeOH (9:1)), to give 30b (12%) as a 
white solid: mp 94-95°C; NMR δH 1.27 (3 H, s, Me), 1.30 (3 H, s, Me) 1.73 (1 H, m, 
CHCHO), 1.84 (1 H, m, CHCHO), 2.29 (1 H, ddd, J = 13.4, 10.8, 5.1 Hz, Pyr-CH), 2.46 (1 H, 
ddd, J = 13.4, 10.4, 5.9 Hz, Pyr-CH), 3.56 (1 H, dd, J = 11.7, 6.1 Hz, CHOH), 3.66 (1 H, dd, J 
= 11.7, 6.1 Hz, CHOH), 4.02 (1 H, dt, J = 8.1, 5.8 Hz, dioxolane 4-H), 4.13 (1 H, q, J = 5.8 
Hz, dioxolane 5-H), 5.04 (2 H, br, NH2), 5.76 (2 H, br, NH2), 7.16 (2 H, d, J = 7.0 Hz, Ar 2,6-
H2), 7.42 (2 H, d, J = 7.0 Hz, Ar 3,5-H2); NMR δC 25.57, 28.04, 28.42, 30.46, 60.90, 76.77, 
77.09, 107.39, 107.94, 129.71, 132.64, 134.29, 160.82, 162.48, 164.40; MS m/z 381.1506 (M 
+ H) (C18H2437ClN4O3 requires 381.1507), 379.1525 (M + H) (C18H2435ClN4O4 requires 
379.1536), 236/234 (M - C7H12O3), 188/186 (M – C8H13ClO3). 
6.46. (4R,5S)-4-(4-(4-Bromophenyl)-4-cyano-3-methoxybut-3-enyl)-2,2-dimethyl-5-hydr-
oxymethyl-1,3-dioxolane (29c) and 5-(4-bromophenyl)-6-(2-((4R,5S)-2,2-dimethyl-5-hyd-
roxymethyl-1,3-dioxolan-4-yl)ethyl)pyrimidine-2,4-diamine (30c) 
Compound 27c/28c was treated with CH2N2, as for the synthesis of 24a, to give 29c (90%) as 
a pale yellow oil: IR νmax 3435, 2243, 1592 cm-1; NMR δH 1.42 (3 H, s, Me), 1.52 (3 H, s, 
Me), 2.38-2.49 (2 H, m, CH2CHO), 2.74-2.80 (2 H, m, CH2C=C), 3.33 (3 H, s, OMe), 3.64 (1 
H, dd, J = 11.1, 5.0 Hz, CHOH), 3.74 (1 H, dd, J = 11.1, 5.0 Hz, CHOH), 4.21-4.27 (2 H, m, 
dioxolane 4,5-H2), 7.29 (2 H, d, J = 8.5 Hz, Ar 2,6-H2), 7.50 (2 H, d, J = 8.5 Hz, Ar 3,5-H2). 
Compound 29c was treated with guanidine, as for the synthesis of 25a (reaction time 10 h, 
chromatographic eluant CHCl3 / MeOH (9:1)), to give 30c (20%) as a white solid: mp 124-
125°C; NMR δH 1.27 (6 H, s, Me2), 1.61-1.79 (2 H, m, CH2CHO), 2.26 (1 H, ddd, J = 13.0, 
10.6, 5.8 Hz, Pyr-CH), 2.46 (1 H, ddd, J = 13.0, 10.6, 5.8 Hz, Pyr-CH), 3.50 (1 H, dd, J = 
11.1, 5.9 Hz, CHOH), 3.54 (1 H, dd, J = 11.1, 5.9 Hz, CHOH), 4.01 (1 H, ddd, J = 9.9, 5.9, 
3.9 Hz, dioxolane 4-H), 4.08 (1 H, q, J = 5.9 Hz, dioxolane 5-H), 7.21 (2 H, d, J = 7.7 Hz, Ar 
2,6-H2), 7.66 (2 H, d, J = 7.7 Hz, Ar 3,5-H2); NMR (CD3OD) δC 24.43, 27.11, 28.49, 30.66, 
60.32, 76.63, 77.89, 107.20, 107.82, 121.84, 132.21, 132.57, 133.50, 160.82, 162.98, 163.71; 
MS m/z 425.1007 (M + H) (C18H2481BrN4O3 requires 425.1011), 423.1019 (M + H) 
(C18H2479BrN4O4 requires 423.1013), 280/278 (M - C7H12O3), 186 (M – C8H13BrO3). 
6.47. (4R,5S)-4-(4-(3,4-Dichlorophenyl)-4-cyano-3-methoxybut-3-enyl)-2,2-dimethyl-5-
hydroxymethyl-1,3-dioxolane (29d) and 5-(3,4-dichlorophenyl)-6-(2-((4R,5S)-5-hydroxy-
methyl-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)pyrimidine-2,4-diamine (30d) 
Compound 27c/28c was treated with CH2N2, as for the synthesis of 24a, to give 29d (91%) as 
a pale yellow oil: IR νmax 3467, 2210, 1597 cm-1; NMR δH 1.40 (3 H, s, 2-Me), 1.50 (3 H, s, 2-
Me), 2.30-2.40 (2 H, m, CH2CHO), 2.72-2.80 (2 H, m, CH2C=C), 3.37 (3 H, s, OMe), 3.58-
3.74 (2 H, m, CH2OH), 4.18-4.26 (2 H, m, 4,5-H2), 7.51 (1 H, d, J = 8.3 Hz, Ar 5-H), 7.84 (1 
H, dd, J = 8.3, 2.0 Hz, Ar 6-H), 8.10 (1 H, d, J = 2.0 Hz, Ar 2-H). Compound 29d was treated 
with guanidine, as for the synthesis of 25a (reaction time 6 h, chromatographic eluant CHCl3 / 
MeOH (9:1)), to give 30d (9%) as a white solid: mp 114-115°C; NMR δH 1.29 (3 H, s, Me), 
1.33 (3 H, s, Me), 1.78 (1 H, m, CHCHO), 1.88 (1 H, m, CHCHO), 2.34 (1 H, m, Pyr-CH), 
2.48 (1 H, m, Pyr-CH), 3.58 (1 H, dd, J = 11.4, 5.9 Hz, CHOH), 3.67 (1 H, dd, J = 11.4, 5.9 
Hz, CHOH), 4.05 (1 H, m, dioxolane 4-H), 4.15 (1 H, q, J = 5.6 Hz, dioxolane 5-H), 4.95 (2 
H, br, NH2), 5.53 (2 H, br, NH2), 7.08 (1 H, dd, J = 8.4, 1.7 Hz, Ar 6-H), 7.38 (1 H, d, J = 1.7 
Hz, Ar 2-H), 7.52 (1 H, d, J = 8.4 Hz, Ar 5-H); NMR δC 25.53, 28.04, 28.12, 30.35, 61.05, 
65.83, 70.51, 106.62, 108.04, 130.15, 131.41, 131.45, 133.51, 134.4, 160.93, 162.22, 168.33; 
MS m/z 417.1091 (M + H) (C18H2337Cl2N4O3 requires 417.1088), 415.1103 (M + H) 
(C18H2337Cl 35ClN4O3 requires 415.1117), 413.1129 (M + H) (C18H2335Cl2N4O3 requires 
413.1147), 272/270/268 (M - C7H12O3) 186 (M – C8H12Cl2O3). 
6.48. Diethyl (R,R)-2,2-diethyl-1,3-dioxolane-4,5-dicarboxylate (32) 
Diethyl (R,R)-2,3-dihydroxybutanedioate 31 (15.0 g, 70 mmol), 2,2-dimethoxypropane (8.0 g, 
80 mmol) and 4-methylbenzenesulfonic acid (66 mg, 0.34 mmol) in dichloromethane (200 
mL) were heated under reflux through activated 4 Å molecular sieves (33 g) in a Soxhlet app-
aratus for 3 h. Na2CO3 (83 mg, 1.0 mmol) was added. Filtration, drying and evaporation gave 
32 (16.0 g, 89%) as a pale buff oil (lit.47 oil): NMR δH 1.32 (6 H, t, J = 7.2 Hz, 2 × CH2CH3), 
1.50 (6 H, s, CMe2), 4.28 (4 H, q, J = 7.2 Hz, 2 × CH2), 4.77 (2 H, s, 4,5-H2). 
6.49. (S,S)-4,5-Di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane (33) 
LiAlH4 (6.0 g, 150 mmol) was heated in dry THF (60 mL) for 30 min. Compound 32 (18.0 g, 
70 mmol) in dry THF (80 mL) was added during 1.5 h. The mixture was heated under reflux 
for 5 h, then cooled to 0ºC. Water (10 mL), aq. NaOH (4 M, 10 mL) and water (30 mL) were 
added. Filtration and evaporation gave 33. The solid was extracted with hot 1,4-dioxane; 
evaporation gave further 33 (total 7.0 g, 60%) as a pale yellow oil (lit.48 oil): NMR δH 1.41 (6 
H, s, Me2), 2.65 (2 H, br, 2 × OH), 3.68-3.78 (4 H, m, 2 × CH2), 3.97 (2 H, m, 4,5-H2). 
6.50. (S,S)-4,5-Di(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane (34) and (S,S)-4-benzyl-
oxymethyl-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane (35) 
NaH (60% oil, 1.4 g, 34 mmol) was stirred in dry DMF (20 mL) under N2 for 30 min. Com-
pound 33 (5.0 g, 31 mmol) in DMF (20 mL) was added dropwise and the mixture was stirred 
for 30 min before BnCl (4.0 g, 32 mmol) was added. The mixture was stirred for 1.5 h, then 
poured into ice-water (250 mL) and extracted thrice with Et2O. The combined extracts were 
washed with water and brine. Drying, evaporation and chromatography (hexane / Et2O 1:1) 
gave 34 (2.2 g, 28%) as a pale yellow oil (lit.49 oil): NMR δH 1.42 (6 H, s, Me2), 3.54-3.66 (4 
H, m, 2 × CH2OBn), 4.02 (2 H, m, 4,5-H2), 4.54 (2 H, d, J = 12.3 Hz, 2 × CHPh), 4.58 (2 H,d, 
J = 12.3 Hz, 2 × CHPh), 7.35 (10 H, m, 2 × Ph-H5). Further elution gave 35 (3.2 g, 64%) as a 
pale yellow oil. [α]20D = +8.0° (c 3.2, CHCl3) (lit.50 [α]23D = +8.2° (c 1.0, CHCl3)); NMR δH 
1.41 (3 H, s, Me), 1.42 (3 H, s, Me), 2.33 (1 H, dd, J = 8.6, 4.3 Hz, OH), 3.55 (1 H, dd, J = 
9.8, 4.3 Hz, CHOBn), 3.64-3.70 (2 H, m, CHOH + CHOBn), 3.75 (1 H, dt, J = 11.7, 4.3 Hz, 
CHOH), 3.94 (1H, dt, J = 8.3, 4.3 Hz, 5-H), 4.05 (1 H, dt, J = 8.3, 4.3 Hz, 4-H), 4.58 (2 H, s, 
CH2Ph), 7.29-7.35 (5H, m, Ph-H5). 
6.51. (4S,5R)-4-Benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-5-carboxaldehyde (4-O-
benzyl-2,3-O-isopropylidene-L-threose) (36) 
Compound 35 (3.6 g, 14 mmol) was stirred with pyridinium chlorochromate (3.6 g, 35 
mmol), NaOAc (300 mg, 3.5 mmol) and powdered 4 Å molecular sieves (3.0 g) in CH2Cl2 
(215 mL) under N2 for 3 h. The mixture was passed through a bed of silica. The silica was ex-
tracted with Et2O. Evaporation of the solvent from the combined filtrate and extract gave 36 
(3.3 g, 93%) as a pale yellow oil: [α]20D = +14° (c 3, CHCl3) (lit.51 [α]20D = +16.2° (c 1, 
CHCl3); NMR δH 1.43 (3 H, s, Me), 1.50 (3 H, s, Me), 3.67 (2 H, d, J = 4.0 Hz, CH2OBn), 
4.19-4.29 (2 H, m, 4,5-H2), 4.58 (1 H, d, J = 10.5 Hz, CHPh), 4.61 (1 H, d, J = 10.5 Hz, 
CHPh), 7.25-7.36 (5 H, m, Ph-H5), 9.76 (1 H, d, J = 1.5 Hz, CHO). 
6.52. Ethyl (Z,4S,5S)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-5-propenoate (37Z) 
and ethyl (E,4S,5S)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-5-propenoate (37E) 
Compound 36 (2.0 g, 8.0 mmol), ethyl triphenylphosphoranylideneacetate (4.2 g, 16 mmol) 
and benzoic acid (50 mg, 0.4 mmol) were heated at reflux in PhMe (200 mL) under N2 for 4 
h. The evaporation residue was extracted thrice with Et2O. Evaporation and chromatography 
(hexane / Et2O 5:1) gave 37Z (800 g, 31%) as a colourless oil (lit.52 oil): NMR δH 1.25 (3 H, t, 
J = 7.1 Hz, CH2CH3), 1.45 (6 H, s, CMe2), 3.68 (2 H, d, J = 3.1 Hz, CH2OBn), 3.97 (1 H, m, 
4-H), 4.12 (2 H, q, J = 7.1 Hz, , CH2Me), 4.56 (1 H, d, J = 12.1 Hz, CHPh), 4.62 (1 H, d, J = 
12.1 Hz, CHPh), 5.38 (1 H, td, J = 8.3, 1.2 Hz, 5-H), 5.92 (1 H, dd, J = 11.7, 1.2 Hz, CHCO2), 
6.18 (1 H, dd, J = 11.7, 8.3 Hz, CH=CCO2), 7.32-7.37 (5H, m, Ph-H5). Further elution gave 
37E (800 mg, 31%) as a colourless oil (lit.53 oil): NMR δH 1.29 (3 H, t, J = 7.0 Hz, CH2CH3), 
1.43 (3 H, s, 2-Me), 1.45 (3 H, s, 2-Me), 3.62 (2 H, d, J = 4.7 Hz, CH2OBn), 3.95 (1 H, dt, J = 
8.6, 4.7 Hz, 4-H), 4.19 (2 H, q, J = 7.0 Hz, CH2Me), 4.42 (1 H, ddd, J = 8.6, 5.5, 1.4 Hz, 5-H), 
4.56 (1 H, J = 12.1 Hz, CHPh), 4.61 (1 H, d, J = 12.1 Hz, CHPh), 6.09 (1 H, dd, J = 15.6, 1.4 
Hz, CHCO2), 6.88 (1 H, dd, J = 15.6, 5.5 Hz, CH=CCO2), 7.27-7.36 (5 H, m, Ph-H5). 
6.53. Ethyl (4S,5S)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-5-propanoate (38) 
A mixture of 37Z and 37E (620 mg, 1.9 mmol) was stirred in EtOH (25 mL) with Pd/C (5%, 
30 mg) under H2 for 1 h. Filtration (Celite®), evaporation and chromatography (hexane / Et2O 
4:1) gave 38 (400 mg, 63%) as a pale yellow oil: [α]20D = -15° (c 4.0, CHCl3); NMR δH 1.23 
(3 H, t, J = 7.0 Hz, CH2CH3), 1.38 (3 H, s, 2-Me), 1.39 (3 H, s, 2-Me), 1.84 (1 H, m, 
CHCH2CO2), 1.96 (1 H, m, CHCH2CO2), 2.37-2.54 (2 H, m, CH2CO2), 3.53-3.60 (2 H, m, 
CH2OBn), 3.80-3.87 (2 H, m, 4,5-H2), 4.12 (2 H, q, J = 7.0 Hz, , CH2Me), 4.56 (1 H, d, J = 
12.3 Hz, CHPh), 4.59 (1 H, d, J = 12.3 Hz, CHPh), 7.32-7.34 (5 H, m, Ph-H5); MS m/z 
323.1856 (M + H) (C19H26O5 requires 323.1858), 265 (M – C3H5O), 91 (Bn). 
6.54. (4S,5S)-5-Benzyloxymethyl-4-(4-cyano-3-oxo-4-phenylbutyl)-2,2-dimethyl-1,3-diox-
olane (39a) / (4S,5S)-5-benzyloxymethyl-4-(4-cyano-3-hydroxy-4-phenylbut-3-enyl)-2,2-
dimethyl-1,3-dioxolane (40a) 
Phenylacetonitrile was condensed with 38, as for the synthesis of 22a/23a, to give 39a/40a 
(14%) as a pale yellow solid: mp 75-77ºC; IR νmax 2206, 1731 cm-1; NMR δH 1.39 (3 H, s, 
Me), 1.41 (3 H, s, Me), 1.86 (1 H, m, CHCHO), 2.00 (1 H, m, CHCHO), 2.48-2.65 (2 H, m, 
CH2C=O), 3.54-3.63 (2 H, m, 4,5-H2), 3.87-3.89 (2 H, m, CH2OBn), 4.57 (1 H, d, J = 12.5 
Hz, CHPh), 4.61 (1 H, d, J = 12.5 Hz, CHPh), 5.59 (1 H, s, CHCN), 7.33-7.64 (8 H, m, Ph’ 
3,4,5-H3 + Ph-H5), 8.11 (2 H, d, J = 7.0 Hz, Ph 2,6-H2); MS m/z 392.1859 (M - H) 
(C24H26NO4 requires 392.1861), 335 (M - C2H4NO), 317 (M – C7H6), 91 (Bn). 
6.55. (4S,5S)-5-Benzyloxymethyl-4-(4-(4-chlorophenyl)-4-cyano-3-oxobutyl)-2,2-di-
methyl-1,3-dioxolane (39b) / (4S,5S)-5-benzyloxymethyl-4-(4-(4-chlorophenyl)-4-cyano-
3-hydroxybut-3-enyl)-2,2-dimethyl-1,3-dioxolane (40b) 
4-Chlorophenylacetonitrile was condensed with 38, as for the synthesis of 22a/23a (chromat-
ographic eluant EtOAc / hexane (1:1)), to give 39b/40b (41%) as a yellow oil: IR νmax 2209, 
1731 cm-1; NMR δH 1.39 (3 H, s, Me), 1.40 (3 H, s, Me), 1.85 (1 H, m, CHCHO), 2.00 (1 H, 
m, CHCHO), 2.46-2.63 (2 H, m, CH2C=O), 3.53-3.62 (2 H, m, 4,5-H2), 3.83-3.87 (2 H, m, 
CH2OBn), 4.57 (1 H, d, J = 12.1 Hz, CHPh), 4.60 (1 H, d, J = 12.1 Hz, CHPh), 7.26-7.40 
(5H, m, Ph-H5), 7.44 (2 H, d, J = 8.6 Hz, Ar 3,5-H2), 8.02 (2 H, d, J = 8.6 Hz, Ar 2,6-H2); MS 
m/z 430.1608 (M + H) (C24H2737ClNO4 requires 430.1599), 428.1623 (M + H) 
(C24H2735ClNO4 requires 428.1628), 372/370 (M – C2H3NO), 91 (Bn). 
6.56. (4S,5S)-5-Benzyloxymethyl-4-(4-(4-bromophenyl)-4-cyano-3-oxobutyl)-2,2-di-
methyl-1,3-dioxolane (39c) / (4S,5S)-5-benzyloxymethyl-4-(4-(4-bromophenyl)-4-cyano-
3-hydroxybut-3-enyl)-2,2-dimethyl-1,3-dioxolane (39c) 
4-Bromophenylacetonitrile was condensed with 38, as for the synthesis of 22a/23a, to give 
39c/40c (24%): as a yellow oil: IR νmax 2208, 1718 cm-1; NMR δH 1.33 (3 H, s, Me), 1.34 (3 
H, s, Me), 1.75 (1 H, m, CHCHO), 1.91 (1 H, m, CHCHO), 2.69 (1 H, m, CHC=O), 2.79 (1 
H, m, CHC=O), 3.55-3.65 (2 H, m, CH2OBn), 3.93 (1 H, m, 5-H), 4.03 (1 H, dt, J = 8.0, 3.7 
Hz, 4-H), 4.53 (1 H, d, J = 12.0 Hz, CHPh), 4.61 (1 H, d, J = 12.0 Hz, CHPh), 7.22 (2 H, d, J 
= 8.1 Hz, Ar 2,6-H2), 7.26-7.36 (5H, m, Ph-H5), 7.53 (2 H, d, J = 8.8 Hz, Ar 3,5-H2); MS m/z 
474.1103 (M + H) (C24H2781BrNO4 requires 474.1102), 472.1103 (M + H) (C24H2779BrNO4 
requires 472.1123), 415/413 (M – C2H4NO), 91 (Bn). 
6.57. (4S,5S)-5-Benzyloxymethyl-4-(4-cyano-3-methoxy-4-phenylbut-3-enyl)-2,2-di-
methyl-1,3-dioxolane (41a) and 6-(2-((4S,5S)-5-benzyloxymethyl-2,2-dimethyl-1,3-diox-
olan-4-yl)ethyl)-5-phenylpyrimidine-2,4-diamine (42a) 
Compound 39a/40a was treated with CH2N2, as for the synthesis of 24a, to give 41a (79%) as 
a pale yellow oil: IR νmax 2208, 1605 cm-1; NMR δH 1.45 (3 H, s, Me), 1.49 (3 H, s, Me), 1.83 
(1 H, m, CHCHO), 1.98 (1 H, m, CHCHO), 2.40-2.59 (2 H, m, CH2C=C), 3.55-3.60 (2 H, m, 
4,5-H2), 3.75 (3 H, s, OMe), 3.81-3.85 (2 H, m, CH2OBn), 4.55 (1 H, d, J = 12.7 Hz, CHPh), 
4.58 (1 H, d, J = 12.7 Hz, CHPh), 7.14-7.45 (10 H, m, 2 × Ph-H5); MS m/z 408.2184 (M + H) 
(C25H30NO4 requires 408.2174), 391 (M - CH4), 380 (M – HCN), 91 (Bn). Compound 41a 
was condensed with guanidine, as for the synthesis of 25a (reaction time 4 h, chromato-
graphic eluant CHCl3 / MeOH (9:1)), to give 42a (67%) as a highly hygroscopic pale yellow 
solid: IR νmax 3454, 1664 cm-1; NMR δH 1.26 (3 H, s, Me), 1.29 (3 H, s, Me), 1.71-1.91 (2 H, 
m, CH2CHO), 2.33 (1 H, ddd, J = 13.5, 10.3, 5.8 Hz, Pyr-CH), 2.45 (1 H, ddd, J = 13.5, 10.5, 
5.7 Hz, PyR-CH), 3.44 (2 H, d, J = 4.6 Hz, CH2OBn), 3.67 (1 H, dt, J = 7.9, 4.6 Hz, 
dioxolane 4-H), 3.75 (1 H, q, J = 4.6 Hz, dioxolane 5-H), 4.28 (1 H, d, J = 12.1 Hz, CHPh), 
4.54 (1 H, d, J = 12.1 Hz, CHPh), 4.64 (2 H, br, NH2), 5.14 (2 H, br, NH2), 7.19-7.43 (10 H, 
m, 2 × Ph-H5); MS m/z 435.2398 (M + H) (C25H31N4O3 requires 435.2396), 327 (M – 
C7H7O), 91 (Bn). 
6.58. (4S,5S)-5-Benzyloxymethyl-4-(-4-(4-chlorophenyl)-4-cyano-3-methoxybut-3-enyl)-
2,2-dimethyl-1,3-dioxolane (41b) and 6-(2-((4S,5S)-5-benzyloxymethyl-2,2-dimethyl-1,3-
dioxolan-4yl)ethyl)-5-(4-chlorophenyl)pyrimidine-2,4-diamine (42b) 
Compound 39b/40b was treated with CH2N2, as for the synthesis of 24a, to give 41b (91%) as 
a pale yellow oil: NMR δH 1.39 (3 H, s, Me), 1.41 (3 H, s, Me), 1.62-1.75 (2 H, m, CH2CHO), 
2.86-2.96 (2 H, m, CH2C=C), 3.52-3.65 (2 H, m, 4,5-H2), 3.81 (3 H, s, OMe), 3.84-3.93 (2 H, 
m, CH2OBn), 4.54 (1 H, d, J = 11.1 Hz, CHPh), 4.58 (1 H, d, J = 11.1 Hz, CHPh), 7.24-7.38 
(9H, m, Ph-H5 + Ar-H4). Compound 41b was condensed with guanidine, as for the synthesis 
of 25a (reaction time 4 h, chromatographic eluant CH2Cl2/MeOH (4:1)), to give 42b (48%) as 
a highly hygroscopic pale yellow solid: IR νmax 3475, 3414, 1618 cm-1; NMR δH 1.28 (3 H, s, 
Me), 1.31 (3 H, s, Me), 1.73 (1 H, m, CHCHO), 1.83 (1 H, m, CHCHO), 2.30 (1 H, ddd, J = 
13.5, 10.5, 5.7 Hz, Pyr-CH), 2.45 (1 H, ddd, J = 13.5, 10.5, 5.7 Hz, Pyr-CH), 3.41-3.49 (2 H, 
m, CH2OBn), 3.66 (1 H, dt, J = 8.2, 3.5 Hz, dioxolane 4-H), 3.51 (1 H, m, dioxolane 5-H), 
4.50 (1 H, d, J = 12.1 Hz, CHPh), 4.54 (1 H, d, J = 12.1 Hz, CHPh), 4.69 (2 H, br, NH2), 5.11 
(2 H, br, NH2), 7.10-7.35 (9 H, m, Ph-H5 + Ar-H4); MS m/z 471.1979 (M + H) 
(C25H3037ClN4O3 requires 471.1976), 469.1999 (M + H) (C25H3035ClN4O3 requires 469.2006), 
363/361 (M – C7H7O), 91 (Bn). 
6.59. (4S,5S)-5-Benzyloxymethyl-4-(-4-(4-bromophenyl)-4-cyano-3-methoxybut-3-enyl)-
2,2-dimethyl-1,3-dioxolane (41c) and 6-(2-((4S,5S)-5-benzyloxymethyl-2,2-dimethyl-1,3-
dioxolan-4yl)-ethyl)-5-(4-bromophenyl)pyrimidine-2,4-diamine (42c) 
Compound 39c/40c was treated with CH2N2, as for the synthesis of 24a, to give 41c (93%) as 
a pale yellow oil: NMR δH 1.39 (3 H, s, Me), 1.41 (3 H, s, Me), 1.78-1.86 (2 H, m, CH2CHO), 
2.85-2.95 (2 H, m, CH2C=C), 3.52-3.68 (2 H, m, 4,5-H2), 3.81 (3 H, s, OMe), 3.84-3.94 (2 H, 
m, CH2OBn), 4.54 (1 H, d, J = 12.1 Hz, CHPh), 4.59 (1 H, d, J = 12.1 Hz, CHPh), 7.22-7.42 
(9 H, m, Ph-H5 + Ar-H4); MS m/z 488.1255 (M + H) (C25H2981BrNO4 requires 488.1259), 
486.1258 (M + H) (C25H2979BrNO4 requires 486.1279), 91 (Bn). Compound 41c was conden-
sed with guanidine, as for the synthesis of 42a, to give 42c (53%) as a highly hygroscopic 
buff solid: NMR δH 1.31 (3 H, s, Me), 1.34 (3 H, s, Me), 1.75 (1 H, m, CHCHO), 1.88 (1 H, 
m, CHCHO), 2.33 (1 H, ddd, J = 13.7, 10.5, 5.9 Hz, Pyr-CH), 2.48 (1 H, ddd, J = 13.7, 10.5, 
5.9 Hz, Pyr-CH), 3.45-3.53 (2 H, m, CH2OBn), 3.70 (1 H, dt, J = 7.8, 3.5 Hz, dioxolane 4-H), 
3.77 (1 H, m, dioxolane 5-H), 4.51 (1 H, d, J = 12.1 Hz, CHPh), 4.57 (1 H, d, J = 12.1 Hz, 
CHPh), 4.76 (2 H, br, NH2), 5.18 (2 H, br, NH2), 7.09 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.28-
7.38 (5 H, m, Ph-H5), 7.54 (2 H, d, J = 8.6 Hz, Ar 3,5-H2); MS m/z 515.1488 (M + H) 
(C25H3081BrN4O3 requires 515.1480), 513.1500 (M + H) (C25H3079BrN4O4 requires 513.1501), 
487/485 (M – C2H5), 407/405 (M - C7H7O), 91 (Bn). 
6.60. 6-((3S,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-phenylpyrimidine-2,4-diamine 
(43a) 
Compound 42a was treated with aq. CF3CO2H, as for the synthesis of 26a, to give 43a (210 
mg, 76%) as a pale buff solid: mp 101-102ºC; NMR (CD3OD) δH 1.70 (1 H, q, J = 7.6 Hz, 2’-
H2), 2.36 (1 H, dt, J = 14.2, 7.6 Hz, 1’-H), 2.48 (1 H, dt, J = 14.2, 7.6 Hz, 1’-H), 3.42-3.55 (4 
H, m, 3’,4’,5’-H4), 4.48 (1 H, d, J = 11.7 Hz, CHPh), 4.52 (1 H, d, J = 11.7 Hz, CHPh), 7.22-
7.49 (10 H, m, 2 × Ph-H5); MS m/z 395.2082 (M + H) (C22H27N4O3 requires 359.2083), 91 
(Bn). 
6.61. 6-((3S,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-(4-chlorophenyl)pyrimidine-2,4-di-
amine (43b) 
Compound 42b was treated with aq. CF3CO2H, as for the synthesis of 26a, to give 43b (75%) 
as a pale yellow solid: mp 141-143°C; IR νmax 3562, 3492, 3430, 3343, 1618 cm-1; NMR 
(CD3OD) δH 1.65-1.73 (2 H, m, 2’-H2), 2.28 (1 H, ddd, J = 13.7, 9.4, 6.6 Hz, 1’-H), 2.42 (1 H, 
ddd, J = 13.7, 9.4, 6.6 Hz, 1’-H), 3.42-3.54 (4 H, m, 3’,4’,5’-H4), 4.48 (1 H, d, J = 11.7 Hz, 
CHPh), 4.52 (1 H, d, J = 11.7 Hz, CHPh), 7.20 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.30-7.36 (5 
H, m, Ph-H5), 7.44 (2 H, d, J = 8.6 Hz, Ar 3,5-H2); MS m/z 431.1680 (M + H) 
(C22H2637ClN4O3 requires 431.1663), 429.1702 (M + H) (C22H2635ClN4O3 requires 429.1693), 
91 (Bn). 
6.62. 6-((3S,4S)-5-Benzyloxy-3,4-dihydroxypentyl)-5-(3-bromophenyl)pyrimidine-2,4-di-
amine (43c) 
Compound 42c was treated with aq. CF3CO2H, as for the synthesis of 26a, to give 43c (95%) 
as a highly hygroscopic pale yellow solid: IR νmax 3582, 3350, 1613 cm-1; NMR (CD3OD) δH 
1.71-1.78 (2 H, m, 2’-H2), 2.36 (1 H, dt, J = 14.6, 7.8 Hz, 1’-H), 2.46 (1H, dt, J = 14.6, 7.8 
Hz, 1’-H), 3.43-3.61 (4 H, m, 3’,4’,5’-H4), 4.51 (1 H, d, J = 11.9 Hz, CHPh), 4.56 (1 H, d, J = 
11.9 Hz, CHPh), 7.18 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.34-7.36 (5 H, m, Ph-H5), 7.63 (2 H, d, 
J = 8.6 Hz, Ar 3,5-H2); NMR (CD3OD) δC 29.26, 31.59, 70.80, 72.32, 71.11, 72.99, 107.30, 
120.98, 122.10, 127.39, 127.58, 128.04, 130.83, 132.31, 138.05, 161.45, 161.80, 162.50; MS 
m/z 475.1184 (M + H) (C22H2681BrN4O3 requires 475.1167), 473.1186 (M + H) 
(C22H2679BrN4O4 requires 473.1188), 91 (Bn). 
6.63. 1-Cyano-7-hydroxy-1-phenylheptan-2-one (45a) / 1-cyano-1-phenylhept-1-en-1,7-
diol (46a) 
Phenylacetonitrile and tetrahydrooxepin-2-one 44 were treated with LiN(SiMe3)2, as for the 
synthesis of 22a/23a, to give 45a/46a (21%) as a pale yellow solid: mp 98-99°C; IR νmax 
3402, 2205, 1718 cm-1; NMR ((CD3)2SO) δH 1.35-1.42 (2 H, m, 5-H2), 1.44-1.51 (2 H, m, 6-
H2), 1.65 (2 H, qn, J = 7.4 Hz, 4-H2), 2.60 (2 H, t, J = 7.4 Hz, 3-H2), 3.40 (2 H, t, J = 6.2 Hz, 
7-H2), 4.36 (1 H, br, OH), 7.20 (1 H, t, J = 7.6 Hz, Ph 4-H), 7.30 (2 H, t, J = 7.6 Hz, Ph 3,5-
H2), 7.61 (2 H, d, J = 7.6 Hz, Ph 2,6-H2); MS m/z 232.1329 (M + H) (C14H18NO2 requires 
232.1337), 214 (M - OH), 185 (M – C2H6O), 115 (M – C6H12O2). 
6.64. 1-(4-Chlorophenyl)-1-cyano-7-hydroxyheptan-2-one (45b) / 1-(4-chlorophenyl)-1-
cyanohept-1-en-1,7-diol (46b) 
4-Chlorophenylacetonitrile and tetrahydrooxepin-2-one 44 were treated with LiN(SiMe3)2, as 
for the synthesis of 22a/23a, to give 45b/46b (11%) as a white solid: mp 92-94°C; NMR δH 
1.21-1.30 (2 H, m, 5-H2), 1.50 (2 H, qn, J = 6.8 Hz, 6-H2), 1.58 (2 H, qn, J = 7.4 Hz, 4-H2), 
2.58 (1 H, dt, J = 18.2, 7.4 Hz, 3-H), 2.66 (1 H, dt, J = 18.2, 7.4 Hz, 3-H), 3.60 (2 H, t, J = 6.8 
Hz, 7-H2), 4.65 (1 H, br, OH), 7.32 (2 H, d, J = 8.4 Hz, Ar 2,6-H2), 7.41 (2 H, d, J = 8.4 Hz, 
Ar 3,5-H2); MS m/z 268.0912 (M + H) (C14H1737ClNO2 requires 268.0918), 266.0942 (M + H) 
(C14H1735ClNO2 requires 266.0947), 250/248 (M – OH), 207/205 (M - C3H8O). 
6.65. 1-(4-Bromophenyl)-1-cyano-7-hydroxyheptan-2-one (45c) / 1-(4-bromophenyl)-1-
cyanohept-1-en-1,7-diol (46c) 
4-Bromophenylacetonitrile and tetrahydrooxepin-2-one 44 were treated with LiN(SiMe3)2, as 
for the synthesis of 22a/23a (chromatographic eluant EtOAc / hexane (3:1)), to give 45c/46c 
(8%) as a pale yellow solid: mp 76-78°C; NMR δH 1.28 (2 H, qn, J = 7.3 Hz, 5-H2), 1.50 (2 
H, qn, J = 7.3 Hz, 6-H2), 1.58 (2 H, qn, J = 7.3 Hz, 4-H2), 2.62 (1 H, dt, J = 18.0, 7.3 Hz, 3-
H), 2.65 (1 H, dt, J = 18.0, 7.3 Hz, 3-H), 3.60 (2 H, t, J = 6.4 Hz, 7-H2), 4.64 (1 H, br, OH), 
7.26 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 7.41 (2 H, d, J = 8.2 Hz, Ar 3,5-H2); MS m/z 312.0430 
(M + H) (C14H1781BrNO2 requires 312.0422), 310.0449 (M + H) (C14H1779BrNO2 requires 
310.0442), 294/292 (M – OH). 
6.66. 1-Cyano-1-(3,4-dichlorophenyl)-7-hydroxyheptan-2-one (45d) / 1-cyano-1-(3,4-
chlorophenyl)hept-1-en-1,7-diol (46d) 
3,4-Dichlorophenylacetonitrile and tetrahydrooxepin-2-one 44 were treated with 
LiN(SiMe3)2, as for the synthesis of 45c/46c, to give 45d/46d (25%) as a pale yellow solid: 
mp 95-97°C; NMR δH 1.26 (2 H, qn, J = 7.3 Hz, 5-H2), 1.53 (2 H, qn, J = 7.3 Hz, 6-H2), 1.62 
(2 H, qn, J = 7.3 Hz, 4-H2), 2.66 (2 H, dt, J = 15.4, 7.3 Hz, 3-H2), 3.60 (2 H, t, J = 6.4 Hz, 7-
H2), 4.69 (1 H, br, OH), 7.39 (1 H, d, J = 8.4 Hz, Ar 6-H), 7.51 (1 H, d, J = 8.4 Hz, Ar 5-H), 
7.83 (1 H, s, Ar 2-H); MS m/z 304.0520 (M + H) (C14H1637Cl2NO2 requires 304.0499), 
302.0537 (M + H) (C14H1637Cl35ClNO2 requires 302.0528), 300.0559 (M + H) 
(C14H1635Cl2NO2 requires 300.0558), 286/284/282 (M – OH). 
6.67. (4R,5R)-4-(2-Cyano-1-oxo-2-phenylethyl)-5-hydroxymethyl-2,2-dimethyl-1,3-diox-
olane (49a) / (4R,5R)-4-(2-cyano-1-hydroxy-2-phenylethenyl)-5-hydroxymethyl-2,2-di-
methyl-1,3-dioxolane (50a) 
Phenylacetonitrile and 2,3-O-isopropylidene–D-erythronolactone 48 were treated with 
LiN(SiMe3)2, as for the synthesis of 22a/23a, to give 49a/50a (27%) as a pale yellow oil: IR 
νmax 3408, 2246, 1694 cm-1; NMR δH 1.41 (3 H, s, Me), 1.49 (3 H, s, Me), 4.41 (1 H, dd, J = 
11.0, 3.5 Hz, CHOH), 4.48 (1 H, d, J = 11.0 Hz, CHOH), 4.75 (1 H, d, J = 5.5 Hz, 4-H), 4.88 
(1 H, m, 5-H), 7.47 (2 H, t, J = 7.4 Hz, Ph 3,5-H2), 7.61 (1 H, t, J = 7.4 Hz, Ph 4-H), 8.10 (2 
H, d, J = 8.6 Hz, Ph 2,6-H2); MS m/z 276.1225 (M + H) (C15H18NO4 requires 276.1235), 258 
(M – OH). 
6.68. (4R,5R)-4-(2-(4-Chlorophenyl)-2-cyano-1-oxoethyl)-5-hydroxymethyl-2,2-dimethyl-
1,3-dioxolane (49b) / (4R,5R)-4-(2-(4-chlorophenyl)-2-cyano-1-hydroxyethenyl)-5-hydr-
oxymethyl-2,2-dimethyl-1,3-dioxolane (50b) 
4-Chlorophenylacetonitrile and 2,3-O-isopropylidene–D-erythronolactone 48 were treated 
with LiN(SiMe3)2, as for the synthesis of 22a/23a, to give 49b/50b (21%) as a pale yellow oil: 
NMR δH 1.30 (3 H, s, Me), 1.59 (3 H, s, Me), 4.05 (1 H, dd, J = 10.1, 3.1 Hz, CHOH), 4.09 (1 
H, d, J = 10.1 Hz, CHOH), 4.86 (1 H, m, 5-H), 4.73 (1 H, d, J = 5.8 Hz, 4-H), 7.27 (2 H, d, J 
= 8.4 Hz, Ar 2,6-H2), 7.48 (2 H, d, J = 8.4 Hz, Ar 3,5-H2); MS m/z 312.0849 (M + H) 
(C15H1737ClNO4 requires 312.0816), 310.0855 (M + H) (C15H1635ClNO4 requires 310.0846), 
294/292 (M – OH). 
6.69. (4R,5R)-4-(2-(4-Bromophenyl)-2-cyano-1-oxoethyl)-5-hydroxymethyl-2,2-dimethyl-
1,3-dioxolane (49c) / (4R,5R)-4-(2-(4-bromophenyl)-2-cyano-1-hydroxyethenyl)-5-hydr-
oxymethyl-2,2-dimethyl-1,3-dioxolane (50c) 
4-Bromophenylacetonitrile and 2,3-O-isopropylidene–D-erythronolactone 48 were treated 
with LiN(SiMe3)2, as for the synthesis of 22a/23a (chromatographic eluant EtOAc / hexane 
(3:1)), to give 49c/50c (38%) as a pale yellow oil: IR νmax 3422, 2208, 1777 cm-1; NMR δH 
1.39 (3 H, s, Me), 1.47 (3 H, s, Me), 4.40 (1 H, dd, J = 10.9, 3.7 Hz, CHOH), 4.45 (1 H, d, J = 
10.9 Hz, CHOH), 4.74 (1 H, d, J = 5.5 Hz, 4-H), 4.87 (1 H, m, 5-H), 5.57 (1 H, s, CHCN), 
7.27 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.51 (2 H, d, J = 8.6 Hz, Ar 3,5-H2); MS m/z 356.0326 
(M + H) (C15H1781BrNO4 requires 356.0320), 354.0327 (M + H) (C15H1779BrNO4 requires 
354.0340), 338/336 (M –OH). 
6.70. (4R,5R)-4-(2-Cyano-2-(3,4-dichlorophenyl)-1-oxoethyl)-5-hydroxymethyl-2,2-di-
methyl-1,3-dioxolane (49d) / (4R,5R)-4-(2-cyano-2-(3,4-dichlorophenyl)-1-hydroxyethen-
yl)-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane (50d) 
3,4-Dichlorophenylacetonitrile and 2,3-O-isopropylidene–D-erythronolactone 48 were treated 
with LiN(SiMe3)2, as for the synthesis of 22a/23a (chromatographic eluant EtOAc / hexane 
(1:1)), to give 49d/50d (22%) as a pale yellow oil: IR νmax 3404, 2250, 1782 cm-1; NMR δH 
1.30 (3 H, s, Me), 1.38 (3 H, s, Me), 3.93 (1 H, dd, J = 10.3, 3.7 Hz, CHOH), 4.00 (1 H, d, J = 
10.3 Hz, CHOH), 4.70 (1 H, d, J = 5.9 Hz, 4-H), 4.91 (1 H, dd, J = 5.9, 3.7 Hz, 5-H), 7.33 (1 
H, dd, J = 8.2, 2.0 Hz, Ar 6-H), 7.36 (1 H, d, J = 8.2 Hz, Ar 5-H), 7.58 (1 H, d, J = 2.0 Hz, Ar 
2-H); MS m/z 348.0411 (M + H) (C15H1637Cl2NO4 requires 348.0397), 346.0901 (M + H) 
(C15H1637Cl35ClNO4 requires 346.0906), 344.0448 (M + H) (C15H1635Cl2NO4 requires 
344.0456), 330/328/326 (M – OH). 
6.71. (4R,5R)-4-(2-Cyano-1-methoxy-2-phenylethenyl)-5-hydroxymethyl-2,2-dimethyl-
1,3-dioxolane (51a) and 6-((4S,5R)-2,2-dimethyl-5-hydroxymethyl-1,3-dioxolan-4-yl)-5-
phenylpyrimidine-2,4-diamine (52a) 
Compound 49a/50a was treated with CH2N2, as for the synthesis of 24a, to give 51a (85%) as 
a pale yellow oil: IR νmax 3492, 2209 cm-1; NMR δH 1.44 (3 H, s, 2-Me), 1.58 (3 H, s, 2-Me), 
3.53 (3 H, s, OMe), 4.39 (1 H, dd, J = 11.0, 3.7 Hz, CHOH), 4.45 (1 H, d, J = 11.0 Hz, 
CHOH), 4.60 (1 H, m, 5-H), 5.37 (1 H, d, J = 7.4 Hz, 4-H), 7.30-7.41 (5 H, m, Ph-H5); MS 
m/z 290.1388 (M + H) (C16H20NO4 requires 290.1392), 274 (M – Me), 258 (M - OMe). 
Compound 51a was treated with guanidine, as for the synthesis of 25a (chromatographic 
eluant CH2Cl2 / MeOH (4:1)) to give 52a (48%) as a pale yellow solid: mp 214-216ºC; IR 
νmax 3492, 3465, 3422, 3318, 3178, 1624 cm-1; [α]20D = +3.3° (c 4, CHCl3); NMR δH 1.21 (3 
H, s, Me), 1.62 (3 H, s, Me), 3.48 (1 H, dd, J = 12.7, 2.1 Hz, CHOH), 3.57 (1 H, dd, J = 12.7, 
3.3 Hz, CHOH), 3.97 (1 H, m, dioxolane 5-H), 4.79 (1 H, d, J = 6.6 Hz, dioxolane 4-H), 4.90 
(2 H, br, NH2), 5.16 (2 H, br, NH2), 7.10 (1 H, d, J = 7.4 Hz, Ph 2-H), 7.31 (1 H, d, J = 7.4 
Hz, Ph 6-H), 7.41 (1 H, t, J = 7.4 Hz, Ph 4-H), 7.47 (2 H, t, J = 7.4 Hz, Ph 3,5-H2); MS m/z 
317.1622 (M + H) (C16H20N4O3 requires 317.1613). 
6.72. (4R,5R)-4-(2(4-Chlorophenyl)-2-cyano-1-methoxyethenyl)-5-hydroxymethyl-2,2-di-
methyl-1,3-dioxolane (51b) and 5-(4-chlorophenyl)-6-((4S,5R)-2,2-dimethyl-5-hydroxy-
methyl-2,2-dimethyl-1,3-dioxolan-4-yl)pyrimidine-2,4-diamine (52b) 
Compound 49b/50b was treated with CH2N2, as for the synthesis of 24a, to give 51b (69%) as 
a pale yellow oil: MS m/z 326.0989 (M + H) (C16H1937ClNO4 requires 326.0973), 324.1014 
(M + H) (C16H1935ClNO4 requires 324.1002), 307/305 (M - H2O). Compound 51b was treated 
with guanidine, as for the synthesis of 52a, to give 52b (50%) as a pale buff solid: mp 172-
174ºC; IR νmax 3497, 3459, 3433, 3396, 3217, 1613 cm-1; NMR δH 1.24 (3 H, s, Me), 1.63 (3 
H, s, Me), 1.66 (1 H, br, OH), 3.47 (1 H, dd, J = 12.8, 2.3 Hz, CHOH), 3.58 (1 H, dd, J = 
12.8, 3.3 Hz, CHOH), 3.98 (1 H, m, dioxolane 5-H), 4.66 (2 H, br, NH2), 4.77 (1 H, d, J = 6.2 
Hz, dioxolane 4-H), 4.93 (2 H, br, NH2), 7.05 (1 H, dd, J = 8.8, 2.0 Hz, Ar 2-H), 7.27 (1 H, 
dd, J = 9.4, 2.0 Hz, Ar 6-H), 7.43 (1 H, dd, J = 8.8, 2.0 Hz, Ar 3-H), 7.47 (1 H, dd, J = 9.4, 
2.0 Hz, Ar 5-H); MS m/z 353.1218 (M + H) (C16H2037ClN4O3 requires 353.1194), 351.1236 
(M + H) (C16H2035ClN4O3 requires 351.1223), 295/293 (M – C3H5O). 
6.73. (4R,5R)-4-(2-(4-Bromophenyl)-2-cyano-1-methoxyethenyl)-2,2-dimethyl-5-hydr-
oxymethyl-1,3-dioxolane (51c) and 5-(4-bromophenyl)-6-((4S,5R)-2,2-dimethyl-5-hydr-
oxymethyl-1,3-dioxolan-4-yl)pyrimidine-2,4-diamine (52c) 
Compound 49c/50c was treated with CH2N2, as for the synthesis of 24a, to give 51c (91%) as 
a pale yellow oil: NMR δH 1.44 (3 H, s, 2-Me), 1.48 (3 H, s, 2-Me), 3.57 (3 H, s, OMe), 4.40 
(1 H, dd, J = 10.9, 3.5 Hz, CHOH), 4.46 (1 H, d, J = 10.9 Hz, CHOH), 4.61 (1 H, m, 5-H), 
5.34 (1 H, d, J = 7.0 Hz, 4-H), 7.36 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.50 (2 H, d, J = 8.6 Hz, 
Ar 3,5-H2); MS m/z 370.0481 (M + H) (C16H1981BrNO4 requires 370.0476), 368.0501 (M + 
H) (C16H1979BrNO4 requires 368.0497). Compound 51c was treated with guanidine, as for the 
synthesis of 52a, to give 52c (29%) as a pale yellow solid: mp 181-183ºC; NMR ((CD3)2SO) 
δH 1.14 (3 H, s, Me), 1.48 (3 H, s, Me), 3.45 (2 H, d, J = 3.5 Hz, CH2O), 4.03 (1 H, dt, J = 6.4, 
3.5 Hz, dioxolane 5-H), 4.73 (1 H, d, J = 6.4 Hz, dioxolane 4-H), 5.70 (2 H, br, NH2), 5.85 (2 
H, br, NH2), 7.20 (1 H, dd, J = 8.1, 2.0 Hz, Ar 2-H), 7.25 (1 H, dd, J = 7.7, 2.0 Hz, Ar 6-H), 
7.61 (1 H, dd, J = 7.7, 2.0 Hz, Ar 5-H), 7.63 (1 H, dd, J = 8.1, 2.0 Hz, Ar 3-H); NMR 
(CD3)2SO) δC 25.44, 26.37, 62.49, 76.46, 79.81, 108.35, 108.72, 121.70, 132.30, 132.35, 
132.59, 133.38, 134.30, 159.21, 162.29, 163.21; MS m/z 397.0694 (M + H) (C16H2081BrN4O3 
requires 397.0698), 395.0712 (M + H) (C16H2079BrN4O3 requires 395.0718). 
6.74. (4R,5R)-2-Cyano-4-(2-(3,4-dichlorophenyl)-1-methoxyethenyl)-2,2-dimethyl-5-
hydroxymethyl-1,3-dioxolane (51d) and 5-(3,4-dichlorophenyl)-6-((4S,5R)-2,2-dimethyl-
5-hydroxymethyl-1,3-dioxolan-4-yl)pyrimidine-2,4-diamine (52d) 
Compound 49d/50d was treated with CH2N2, as for the synthesis of 24a, to give 51d (78%) as 
a pale yellow oil: IR νmax 3534, 2247, 1595 cm-1; NMR δH 1.44 (3 H, s, 2-Me), 1.47 (3 H, s, 2-
Me), 3.72 (3 H, s, OMe), 4.54 (1 H, dd, J = 10.7, 4.1 Hz, CHOH), 4.73 (1 H, d, J = 10.7 Hz, 
CHOH), 4.96 (1 H, m, 5-H), 5.52 (1 H, d, J = 5.9 Hz, 4-H), 7.15 (1 H, d, J = 8.5 Hz, Ar 5-H), 
7.37 (1 H, dd, J = 8.5, 1.4 Hz, Ar 6-H), 7.40 (1 H, d, J = 1.4 Hz, Ar 2-H); MS m/z 360.0378 
(M - H) (C16H1637Cl2NO4 requires 360.0397), 358.0433 (M - H) (C16H1637Cl35ClNO4 requires 
358.0426), 356.0452 (M - H) (C16H1635Cl2NO4 requires 356.0456), 346/344/342 (M – Me). 
Compound 51d was treated with guanidine, as for the synthesis of 52a, to give 52d (47%) as 
a pale yellow solid: mp 181-183ºC; NMR (CD3CN) δH 1.20 (3 H, s, Me), 1.49 (3 H, s, Me), 
3.40-3.42 (2 H, m, CH2OH), 4.03 (1 H, m, 5-H), 4.72 (1 H, d, J = 7.0 Hz, 4-H), 5.21 (2 H, br, 
NH2), 5.31 (2 H, br, NH2), 7.11 (0.5 H, dd, J = 8.2, 2.0 Hz, Ph 6-H), 7.21 (0.5 H, dd, J = 8.2, 
2.0 Hz, Ph 6-H), 7.38 (0.5 H, d, J = 2.0 Hz, Ph 2-H), 7.48 (0.5 H, d, J = 2.0 Hz, Ph 2-H), 7.60 
(0.5 H, d, J = 8.2 Hz, Ph 5-H), 7.62 (0.5 H, d, J = 8.2 Hz, Ph 5-H); NMR (CD3)2CO) δC 24.90 
(Me), 25.88 (Me), 61.93 (CH2OH), 76.13 (CH), 79.16 (CH), 107.43 (CMe2), 108.75 (Pyr 5-
C), 130.36 (Ph C), 131.07 (Ph CH), 131.18 (Ph C), 131.51 (Ph CH), 132.89 (Ph CH), 135.14 
(Ph C), 159.37 (Pyr 2-C), 161.93 (Pyr 4-C), 162.93 (Pyr 6-C); MS m/z 389.0778 (M + H) 
(C16H1937Cl2N4O3 requires 389.0775), 387.0810 (M + H) (C16H1937Cl35ClN4O3 requires 
387.0833), 385.0833 (M + H) (C16H1935Cl2N4O3 requires 385.0834), 331/329/327 (M –
C3H5O). 
6.75. 1-Cyano-1,4-diphenylbutan-2-one (54) / 1-cyano-1,4-diphenylbut-1-en-2-ol (55) 
Phenylacetonitrile was condensed with ethyl 3-phenylpropanoate 53, as for the synthesis of 
22a/23a, to give 54/55 (34%) as a pale buff solid: mp 53-54ºC (lit.54 mp 76-78°C) ; IR νmax 
2200 cm-1; NMR ((CD3)2SO) δH 2.88 (2 H, t, J = 6.4 Hz, CH2), 2.94 (2 H, t, J = 6.4 Hz, CH2), 
7.20-7.61 (10 H, m, 2 × Ph-H5), 11.70 (1 H, br s, OH) MS m/z 250.1240 (M + H) (C17H16NO 
requires 250.1231), 222 (M – HCN), 91 (Bn). 
6.76. 1-Cyano-1-phenylpropan-2-one (58) / 1-cyano-1-phenylprop-1-en-2-ol (59) 
Phenylacetonitrile was condensed with ethyl acetate 58, as for the synthesis of 22a/23a except 
that chromatography was omitted and the product was recrystallised (aq. EtOH), to give 58/59 
(31%) as a pale buff solid: mp 87-88ºC (lit.55 mp 87-89ºC); NMR δH 2.25 (3 H, s, Me), 4.66 
(1 H, s, CHCN), 7.38-7.47 (5 H, m, Ph-H5); MS m/z 160.0740 (M + H) (C10H10NO requires 
160.0762), 144 (M - CH3), 118 (M – C2H3N). 
6.77. 1-(4-Chlorophenyl)-1-cyanobutan-2-one (68) / 1-(4-chlorophenyl)-1-cyano-but-1-
en-2-ol (64) 
4-Chlorophenylacetonitrile was condensed with ethyl propanoate 62, as for the synthesis of 
22a/23a, to give 62/63 (31%) as a pale yellow solid: mp 50-51ºC (lit.16 mp 50-52ºC); NMR 
((CD3)2SO) δH 1.24 (3 H, t, J = 7.4 Hz, Me), 2.62 (2 H, q, J = 7.4 Hz, CH2), 7.42 (2 H, d, J = 
8.8 Hz, 2,6-H2), 7.66 (2 H, d, J = 8.8 Hz, 3,5-H2). 
6.78. Biological assay 
The radial spoke assay was performed essentially as described by Gerum et al.38 and Sibley et 
al.56 The three yeasts were grown in media comprising 10% yeast extract, 10% peptone and 
10% dextrose. Sulfanilamide (1.0 mM, 100 µL), an inhibitor of dihydropteroate synthase,57 
was spread onto fresh agar plates and allowed to absorb into the medium overnight. Three 
template plates were streaked with the yeast cultures in two orthogonal lines and incubated at 
30°C for 3 d. These plates were used to generate replica test plates. Test compounds 7a-d, 8a-
c, 9a-d, 10a-d and control compounds 3, 6, 11, 12 were made up as 10 mM solutions in 
DMSO; a spot (10 μL) of each of these solutions was placed at the centre of each test plate. 
The assay plates were then incubated for 3 days at 30ºC before the inhibition zone was 
measured. Each compound/yeast combination was assayed in triplicate. 
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Table 1.  Diameters of zones of inhibition of growth of S. cerevisiae carrying the DHFR gene from M. tuberculosis, S. cerevisiae carrying the 
human DHFR gene and wild-type S. cerevisiae by test pyrimidine-2,4-diamines 7-10 and by control pyrimidine-2,4-diamines 11, 12, 3 
(pyrimethamine) and 6 (trimethoprim). 
 
Compound R3’ R4’ R6 Diameter of zone 
of inhibition (mm) 
S. cerevisiae 
(TB-DHFR)a,b 
Diameter of zone 
of inhibition (mm) 
S. cerevisiae 
(human-DHFR)a,c 
Diameter of zone 
of inhibition (mm) 
S. cerevisiae 
(yeast-DHFR)a,d 
7a H H (3R,4S)-3,4,5-trihydroxypentyl 11 6 6 
7b H Cl (3R,4S)-3,4,5-trihydroxypentyl 9 7 7 
7c H Br (3R,4S)-3,4,5-trihydroxypentyl 7 6 8 
7d Cl Cl (3R,4S)-3,4,5-trihydroxypentyl 8 8 8 
8a H H (3S,4S)-3,4,5-trihydroxypentyl 9 8 8 
8b H Cl (3S,4S)-3,4,5-trihydroxypentyl 7 7 6 
8c H Br (3S,4S)-3,4,5-trihydroxypentyl 8 5 6 
9a H H 5-hydroxypentyl 7 7 9 
9b H Cl 5-hydroxypentyl 8 8 8 
9c H Br 5-hydroxypentyl 8 8 9 
N
N
NH2
H2N R6
R4'
R3'
9d Cl Cl 5-hydroxypentyl 9 9 9 
10a H H (1S,2R)-1,2,3-trihydroxypropyl 5 5 5 
10b H Cl (1S,2R)-1,2,3-trihydroxypropyl 5 5 5 
10c H Br (1S,2R)-1,2,3-trihydroxypropyl 5 5 5 
10d Cl Cl (1S,2R)-1,2,3-trihydroxypropyl 8 8 7 
20 H H 2-phenylethyl 5 5 5 
12 H H Me 7 8 8 
3 (pyrimethamine) Cl H ethyl 5 6 5 
6 (trimethoprim)    5 6 6 
DMSO negative 
control 
   5 6 5 
a Diameters of the zone of inhibition were measured for each of the orthogonal streaks on each of at least three test plates for each determination; 
data are expressed ± 1 mm. 
b TB5 yeast engineered to contain DHFR from M. tuberculosis only. 
c TB5 yeast engineered to contain human DHFR only. 
c TB5 yeast engineered to contain yeast DHFR only. 
 
